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ABSTRACT OF DISSERTATION

ELUCIDATING THE ROLE OF THE TYROSINE PHOSPHATASE, SHP-2, IN
REGULATION OF PD-L1 EXPRESSION IN NON-SMALL LUNG CANCER
USING BOTH BIOCHEMICAL ANALYSES AND REAL-WORLD GENOMIC
INFORMATION
Immune checkpoint inhibitors (ICIs), especially those that target
programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PDL1), have been shown to provide substantial clinical benefit in many patients with
non-small cell lung cancer (NSCLC). While these therapeutic agents can be highly
effective in the correct context, the biological systems that malignant cells draft
from normal activities of the cell are poorly characterized. Tumor cell-specific
expression of PD-L1 is likely important for clinical benefit from PD-1 and PD-L1
inhibitors. It is known that PD-L1 is inappropriately expressed in many cancers
harboring mutations in the RAS family of genes. The KRAS gene is mutated in as
many as 30% of NSCLC tumor and drives tumor proliferation. Because there are
no FDA-approved KRAS-targeting agents available for NSCLC patients, ICI
therapy has been used in patients with tumors harboring mutations in the KRAS
gene with clinical success. However, utilization of these therapies will remain
hindered until there is a more complete understanding of the mechanisms
governing the expression of targets of ICIs, specifically of PD-L1. The work in this
dissertation explores the role of the tyrosine phosphatase, SHP-2. SHP-2 has
been scrutinized as an important signaling molecule in a variety of cancers that
links the activity of several signaling cascades as a regulator of KRAS, resulting
in the clinical development of inhibitors of SHP-2. The work encompassed in these
studies takes two complementary approaches to explore the role of SHP-2 in
control of PD-L1 expression. First, publicly available real-world genomic
information was used to establish a connection between the activity and/or
expression of SHP-2 and PD-L1 in tumors and how expression relates to response
to ICI therapy. Second, this work further sought to elucidate the molecular
mechanism by which SHP-2 impacts the expression of PD-L1 in an NSCLC cell
line model system. From these investigations, this work established that SHP-2
and PD-L1 have an expression relationship in clinical samples that may impact
response to ICI therapies and experimentally identified a possible mechanism by
which SHP-2 impacts PD-L1 expression in NSCLC.
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CHAPTER 1.
1.1

INTRODUCTION
Cancer, at its most fundamental level, is a disease characterized by

abnormal cells that divide without control and can invade nearby tissues (1). While
correct and concise, this deceptively simple definition only scratches the surface
of the answer to the question ‘What is cancer?’ Within the past 100 years, the
burden of cancer has evolved in a manner that mirrors the pathology of the
disease itself. In 1900, the leading causes of death in the USA were primarily due
to both bacterial and viral infections, with cancer accounting for 64 deaths per
100,000 people. Between 1900 and 2010 overall mortality from all causes declined
by 54%, yet the rates of death due to cancer increased roughly 300%, resulting in
cancer as one of the leading causes of death, second only to heart disease by
2019 (2). The decline in deaths due to infectious disease and subsequent
increases in lifespan may largely be attributed to the development of antibiotics
and vaccines (3). As a result, the physiological landscape upon which human
disease occurs was ever altered, facilitating the emergence of illnesses that arise
not from extrinsic factors such as pathogens, but rather from malfunctions of our
own biology that become more apparent as lifespan increases. This shift in
mortality reveals much about the nature of this ever-changing affliction, and so
one may think of cancer as a pathology not of the human body, but of the human
evolution.

The evolution of an organism requires three core criteria to occur:
reproduction, variation, and selective pressure. The increase in life expectancy
over the last century and how it relates to cancer reflects one of these core
evolutionary principles: reproduction. It is thought that, among many factors, the
escalation in cancer mortality over the last century can primarily be attributed to a
large increase in life expectancy. In 1900 the average life expectancy at birth was
47 years, compared to 79 years by 2010 (2). As an individual grows past the point
1

in their life at which they may bear offspring, their continued existence becomes
evolutionarily disadvantageous to their species. That is to say that, from a purely
evolutionary standpoint and from the perspective of a low population, newly
developing species, there are diminishing returns on the usefulness of an
individual that can no longer reproduce. Once older individuals can no longer serve
a caretaker role and must instead be taken care of, in times when there is great
pressure to survive, older individuals take more time, energy and resources than
they provide. As such, there is minimal evolutionary incentive for the development
of biochemical mechanisms which prevent the onset of cancer later in life, at least
as is the case in homo sapiens. However, there do exist numerous biochemical
mechanisms aimed at restraining genetic variance throughout the ages of
reproductive capability and onward. Whether it be by detecting and eliminating
sources of genetic lesions, preventing the unregulated replication of individual
cells, or carefully curating the integrity of the genome itself, our bodies every
attempt to cull the inception and progression of cancer aims to minimize the
probability of potentially detrimental genetic mutations.

The corrupted application of selective pressure by cancerous cells,
specifically with regard to the development of anti-cancer therapies, has revealed
itself as one of the greatest obstacles in the effective treatment and control of
disease progression. A longstanding issue in the use of drugs to combat the growth
of pathogenic organisms has been their ability to acquire resistance to therapeutic
intervention. Bacterial cells rapidly evolve under the selective pressure of drugs
that impede their ability to properly divide, and malignant human cells possess the
same capabilities but to a substantially more sophisticated extent. Methicillinresistant Staphylococcus aureus (MRSA) is a relatively simple single cell organism
that has imposed major challenges in the development of antibacterial drugs.
MRSA’s genome contains some 2.8 million base pairs which encode roughly 2,629
coding sequences, about 10-fold fewer coding sequences than the human genome
(4). When one compares the complexity of, and challenges posed by prokaryotic
mechanisms of drug resistance against the highly adaptive, multiplex, and
2

intersecting pathways applied by eukaryotic cells to the same end, the task of
overcoming tumoral drug resistance appears incredibly difficult. It is important to
consider that the generation of random genetic mutations is a naturally occurring
process that leads to phenotypic changes which may or may not be advantageous
to an organism. When a rapidly and haphazardly reproducing population of
heterogenous cells is put under the selective pressure of pharmacological
intervention, their ability to exponentially evolve past even the most efficacious of
therapies is unveiled as the true obstacle in cancer drug development.

Of all the drugs which enter clinical trials for the treatment of cancer, a dismal
97% of them fail to receive FDA approval, the lowest among all drug indications
(5). The consequences of these failures are enormous; by the time a drug reaches
late phase clinical trials, hundreds of millions of dollars and years of time have
been invested in its development (6). Furthermore, most of these clinical failures
stem not from issues in the toxicity or pharmacokinetics of a drug as one might
predict. Rather, these failures are the result of inadequacies in drug efficacy, the
cause of which is often indiscernible until later phase clinical trials and may be
attributed to unforeseen downstream cellular processes that remain poorly
understood (7)(8). Despite our best efforts to predict the success of a drug with
preclinical modeling, when they finally reach a human subject, the drugs simply do
not work. The decision for which anti-cancer compound is chosen to treat a tumor
is based upon the mechanism of action that would prove most effective in stopping
that tumor’s growth. If we do not fully understand the mechanism of a compound,
that is to say the drug isn’t doing exactly what we ‘think’ it’s doing, it drastically
impairs our ability to utilize our treatments to their full potential. Thus, the failure to
completely understand and fully characterize all the facets of how a drug, its target,
and the downstream effectors of that target function within an actual tumor has
created a wildly unsustainable system for cancer drug development.

The ancient Chinese military strategist, Sun Tzu, once wrote in The Art of
War, “If you know your enemy as you know yourself, you will fight without fear in
3

100 battles. If you know yourself but not your enemy, with every victory gained you
will also suffer defeat.” Though he wrote this regarding military strategy, this
proverb lends relevancy to the war against cancer. Despite the ongoing
development of highly sophisticated targeted therapies, cancers continue to
evolve, adapt, and overcome our best efforts in manners we remain unable predict.
Although we create groundbreaking new therapies which drastically improve the
lives of those with previously untreatable cancer, we often fail to predict for whom
they will work, how they work, and when they do not work- why not. The enemy
now standing in opposition of humanity is cancer, and cancer at its most
fundamental level, is evolution. To fully understand how human cells can evolve
and overcome our efforts to eradicate them, we must understand as completely as
possible every component of every biological process by which cancer cells evade
destruction and consume their host.

Thus, to fully utilize any cancer treatment, we must focus our efforts into
thoroughly defining every complexity of a drug and its mechanism of action. The
factors that control the expression, activity, epigenetic regulation, metabolic
turnover, parallel and intersecting pathways, downstream and upstream effectors
of the target are all important for discerning the right therapy for the right
patient/tumor at the right time. The work herein aims to further elucidate the
complexities of the regulation of programmed cell death ligand 1 (PD-L1)
expression, the target of some of the most successful cancer therapies to date.

1.2

BIOLOGY OF NSCLC

Hallmarks of cancer
At its most basic level, cancer is the uncontrolled and unregulated replication
of a cell. However, there are a variety of cellular mechanisms by which this
outcome can be achieved. Canonically, these defining biochemical capabilities
have been historically separated into ten distinct categories described a decade
ago by Hanahan and Weinberg (9). Depending on the type of cancer and the tissue
4

of origin, the acquisition of several of these capabilities may allow a cell to evolve
into cancer, with very late-stage cancers having the potential to encompass all ten,
heavily contributing to the innate heterogeneity of the disease. These ten hallmarks
of cancer can be broadly grouped by the mechanism by which they promote
unregulated cell growth, and will be expanded on in the forthcoming sections; 1)
the recruitment or corruption of extrinsic tissues to assist in tumor development 2)
the disruption of cellular checks and balances designed to prevent the occurrence
and progression of cancer 3) the exploitation of intrinsic signaling or genetic
pathways related to cellular growth or 4) strategies to evade and/or manipulate the
immune system.

Recruitment or corruption of extrinsic tissues
In order for a tumor to continue growing beyond the normal limitations of its
tissue of origin, it must have a proper supply of oxygen and nutrients and be able
to survive in an irregular growth environment. The two major mechanisms by which
cancer will coerce neighboring tissues to assist in its progression are by inducing
angiogenesis, or by invading the nearby tissues directly through the process of
metastasis. The notion that a critical part of tumor progression was the recruitment
of blood vessels to supply the growing tumor mass with nutrients was initially met
with great resistance. Judah Folkman, the so-called ‘father of angiogenesis’ in
1971 defined angiogenesis as “a cascade of processes emanating from
microvascular endothelial cells in response to soluble factors” hypothesizing that
developing tumors were being limited in their growth by an inability to acquire
enough oxygen and mitogenic factors, and that only by recruiting blood vessels to
fuel their growth could tumors develop into later, deadlier stages of disease (10).
Over time, further insight was gained to confirm this hypothesis and led to the
discovery of a number of growth factors known to induce angiogenesis, namely
proteins such as vascular endothelial growth factor (VEGF) and hypoxia-inducible
factor alpha (HIF-a). As such, drugs which interfere with these pathways reduce
the recruitment of blood vessels and subsequent blood flow to tumors thus serving
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as viable therapeutic options for a variety of tumor types, though not many are
used in the clinic today.

Perhaps the most deleterious characteristic of advanced cancer is its ability
to invade or spread to other tissues in a process known as metastasis. Though
one of the deadliest properties of the disease, metastasis is a highly inefficient
process that requires numerous specific biological conditions to be met then
resulting in the development of heterogenous cell populations capable of surviving
outside of their tissue of origin (11). This ultimately leads to the development of
secondary tumors, typically to highly vascularized tissues such as the liver, brain,
and lungs. Chemotherapy, a branch of therapy which damages and hinders
actively proliferating cells non-discriminately throughout the entire body, has
served as an effective treatment strategy to prevent cells which have been shed
from the primary tumor from forming a colony and replicate in secondary tissues.

Disruption of cellular checks and balances

For a cell to transition into malignancy, a loss of function in mechanisms that
restrict unregulated cell growth must occur in addition to oncogenic mutations that
drive proliferation. The enabling of replicative immortality, ability to resist
programmed mechanisms of cell death, and evasion of growth suppressors are all
methods cancer applies to subvert such preventative measures. When describing
the ability of a cell to become ‘immortal’ it is important to note that this refers not
to any single cell being able to resist death, but rather to the loss of genetic
limitations designed to limit the number of times any individual cell may replicate.
The ‘Hayflick phenomenon’ describes the limited number of times a primary cell
population in culture will divide until cellular division stops and the cell enters a
state in which it will no longer continue to undergo mitosis known as senescence
(12). Cellular senescence is thought to be a natural process that occurs in most
somatic tissue and in general can be thought of as “cellular aging”. It has been
hypothesized that the principle of senescence is an evolutionary mechanism
6

specifically intended to reduce the likelihood of cancer occurring by restricting the
total number of times a cell can replicate. Each time a cell divides there-in lies the
potential for the occurrence of errors while creating copies of genetic code. By
imposing an upper limit to the number of times which a cell may divide, the
maximum potential for mutations during mitosis is reduced, thus diminishing the
likelihood of a cell becoming cancerous. Importantly, the number of times a cell is
programmed to divide is also governed by what type of cell it is and what functions
that cell serves. For example, a neuron almost never divides, whereas enterocytes
may divide indefinitely.

The biochemical mechanism that exerts this self-imposed senescence
manifests in the form of GC rich DNA sequences located at the ends of linear
eukaryotic chromosomes known as telomeres. Telomeres function as protective
‘caps’ for the ends of chromosomes and are created by the enzyme telomerase, a
specialized reverse transcriptase that adds back telomeric DNA to the ends of
chromosomes. Over time, somatic tissues will gradually lose expression of
telomerase, resulting in the shortening of telomeric DNA (13). After enough
telomeric DNA has been lost, the shortened telomeres are recognized by the cell
as double-strand breaks, which will then lead to large amounts of genomic
instability and chromosomal aberrations triggering p53 modulated senescence or
apoptosis. To subvert the natural process of cellular senescence, cancer cells
have been shown to inappropriately express telomerase, thus preventing the loss
of telomeric DNA (14). This revelation has prompted the development of
telomerase inhibitors currently undergoing clinical trials.

A characteristic shared by nearly every subtype of cancer is the ability to
deter or otherwise evade cellular signaling events that result in self-mediated cell
death processes such as apoptosis, anoikis, or autophagy. Unlike cellular necrosis
which happens in a fast, non-programmed fashion, these processes involve a
variety of finely coordinated cellular signaling cascades that result in the controlled
breakdown of organelles, proteins, and genetic material. Proteins such as Bax/Bcl7

2 and the caspase family of proteins are heavily involved in transmitting and
regulating signal cascades that induce apoptosis to control DNA damage resulting
from unregulated cellular growth and division. It is well understood that the loss or
dysfunction of these proteins has been strongly correlated to the progression of
cancer.

In addition to the evasion of both intracellular and extracellular stimuli that
initiate programmed-cell death, another hallmark of cancer is the inactivation of
tumor suppressor genes. Tumor suppressor genes contribute to the normal
development of healthy cells by controlling DNA damage and cell cycle
progression. These genes have gained the title of “tumor suppressors” by
influencing processes that stifle the growth and survival of cells that would
otherwise progress to malignancy (15). They do this in a number of ways: inhibiting
cell growth and division, promoting apoptosis, preventing or hindering genetic
change, inhibiting angiogenesis, and inhibiting metastasis. The gene TP53
encodes the tumor suppressing protein p53, one of the most well characterized
tumor suppressors. A transcriptional activator, p53 functions to regulate the
expression of a multitude of genes that influence growth, DNA damage and repair,
and apoptosis (16).

Sustained cell signaling
Cancer results from the uncontrolled replication of a cell population. To
maintain unregulated proliferative signaling, cancer cells may utilize any number
of signal transduction pathways related to proliferation and survival. Depending on
cancer subtype, the number of unique signaling pathways it co-opts may vary
greatly, highlighting not only the inherent variance within a single cancer subtype,
but also between cancer subtypes. For example, it is not uncommon for leukemias
to only require a single oncogenic driver mutation to maintain sustained cellular
signaling and progress to malignancy. The tyrosine-protein kinase ABL1 is
frequently mutated in leukemias, often through a chromosomal translocation at
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t(9;22) that results in the fusion of breakpoint cluster region protein (BCR) with
ABL1, distorting the regulatory domains of ABL1 resulting in a constitutively active
protein kinase that continuously initiates or sustains cell signaling cascades related
to cell division, adhesion, and resistance to apoptosis (17).

In addition to the BCR-ABL fusion protein, many additional oncogenic driver
proteins are also kinases responsible for activating signal transduction pathways.
Epidermal growth factor receptor (EGFR/Her-2) is a receptor tyrosine kinase
commonly mutated in NSCLC and breast cancer, with mutations that result in
constant phosphorylation of substrate proteins (18). Phosphoinsolitol-3-kinase
(PI3K) is responsible for phosphorylating lipids that transmit signals within the
AKT/mTOR pathway resulting in the constant activation of this cellular growth
pathway. Janus kinase (JAK) is responsible for activating cell signaling cascades
involving the signal-transducer and activator of transcription (STAT) family of
proteins. Given the heavy involvement of protein phosphorylation within these
growth and survival pathways, protein phosphatases such as Src-homology
containing protein 2 (SHP-2) and phosphatase and tensin homolog (PTEN) have
been shown to function as negative regulators of these pathways, and a loss in
their activity or expression has been linked to tumor progression (19).

Inflammation and the avoidance of immune detection

Outside of the intracellular processes occurring within the tumor itself, there
are extrinsic biological systems that influence tumor development, not the least of
which is the immune system. It has long been understood that there is a great deal
of interplay between the immune system and the tumor itself, however until
recently, the importance of the immune response on tumor development had not
been thoroughly researched. One of the primary functions of the immune system
is to identify and eliminate cancer through the recognition of mutant proteins that
may result in tumorigenesis, a process known as immune surveillance. The
manner in which the immune system does this is highly complex and involves
9

many different immune cell types. CD4+ helper T-cells identify cancerous
neoepitopes and mobilize natural killer (NK) cells and cytotoxic CD8+ T-cells to
eliminate them. Additionally, immune cells secrete immunomodulatory or
inflammatory molecules such as cytokines or antibodies which are produced by Bcells. This persistent activity of the immune system against an identified tumor
often results in prolonged chronic inflammation (20).
Eventually, a tumor can accumulate mutations to evolve to the final ‘escape
phase’ in which it applies several mechanisms such as antigenic modulation, tumor
induced privileged sites, and tumor-induced immune suppression to completely
elude immune detection. However, therapies which disrupt these mechanisms of
immune evasion and ‘unmask’ the tumor to the immune system have
demonstrated immense clinical benefit in recent years. Immunotherapy first began
in the early 20th century when Dr. William B. Coley would inject mixtures of live
and attenuated streptococcus into patient tumors to induce a localized immune
response (21). In recent years, monoclonal antibodies developed against
immunosuppressive proteins such as programmed death protein 1 (PD-1) and its
ligand (PD-L1) have revolutionized the field of cancer therapy and will be
discussed in greater detail in later chapters.

Biology and epidemiology of NSCLC

Of all cancer types, lung cancer, non-small cell lung cancer (NSCLC)
specifically, may be the most burdensome on the American healthcare system. It
is the leading cause of cancer deaths each year both world-wide and within the
US, accounting for nearly 22% of all deaths due to cancer (22). Furthermore, the
Commonwealth of Kentucky suffers the highest rates of death due to lung cancer
in the entire country, likely attributable to the high rates of smoking (22).

Lung cancer can be divided into two groups, the more prevalent and slower
growing NSCLC, and the less common but more aggressive small cell lung cancer
10

(SCLC). NSCLC can be further divided into two major histological groups, lung
squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). LUSC is a
slow growing form of the diseases and originates from squamous cells; a type of
epithelial cell that lines the inside airways of the lungs. LUAD arises from glandular
cells that are found within the smaller airways and alveoli and has the tendency to
progress less quickly than other lung cancers. Although all types of lung cancer
are associated with smoking, the association is strongest with LUSC when
compared to LUAD. LUAD is the most common lung cancer histology amongst
non-smokers (23). The most prominent risk factor for NSCLC is tobacco use,
contributing to greater than 80 percent of lung cancer deaths. Additional risk
factors include pre-existing conditions such as COPD or previous aerodigestive
malignancies, genetic predispositions, or exposure to carcinogenic compounds
such as asbestos, radon, and arsenic (24).

Although many cancers can be divided into discrete subgroups based upon
their histology, tissue, and cell type of origin, the heterogeneity of the disease from
a molecular standpoint cannot be overstated. There have been numerous studies
which have established high intratumor heterogeneity as a negative prognostic
indicator, characterized by factors such as tumor mutational burden (TMB),
chromosome instability (CIN), and copy number variation (CNV) (25)(26)(27)(28).
NSCLC, specifically, is well understood to be a highly heterogenous disease which
likely contributes to the challenges posed in identifying effective therapies that
provide durable and long-lasting clinical benefit (29). There are likely many
reasons for the genetic diversity of NSCLC; however, the consistent DNA damage
induced by tobacco use over a long period of time has been hypothesized to be a
major contributing factor (30). Importantly, as we continue to develop our
understanding of cancer and its ever-increasing complexity, this heterogeneity
highlights the value of mechanistic studies to elucidate the molecular workings of
the disease. Though not always immediately apparent, the eventual clinical
translatability of such work may function to attenuate previous failures in attempts

11

to develop efficacious treatments that eventually become FDA-approved therapies
(31)(32).

In LUAD, mutations in the genes encoding KRAS and EGFR are extremely
common and detected in 32% and 27% of LUAD tumors, respectively. In addition
to these well-characterized oncogenes, activating mutations in other genes such
as BRAF, ALK, MET, and ROS play an important role in the development of LUAD.
Mutations in tumor suppressor genes such as TP53, STK11, and PTEN are all
common in LUAD, with nearly 50% of LUAD tumors harboring inactivating
mutations in the TP53 gene (33).

Biology of KRAS

The KRAS protein (Kirsten rat sarcoma 2 viral oncogene homolog), encoded
by the KRAS gene, is a small, membrane-associated GTPase that functions to
transmit external cellular signaling events to the nucleus. It belongs to a large
superfamily of genes that encode small GTPases, and more specifically the
subfamily known as the Ras family of genes. The RAS proteins include the three
highly homologous proteins HRAS, NRAS, and KRAS. The KRAS protein contains
a GTP binding pocket that serves to switch between its active GTP-bound state
and its inactive GDP-bound state. Furthermore, this GTP-binding pocket is found
within its G-domain, a region of the protein where downstream effectors may bind
and intimate cellular signaling cascades. The balance of these two states is
controlled by guanine nucleotide exchange factors (GEFs) which catalyze the
transition from GDP-bound KRAS to a GTP-bound state, and GTPase-activating
proteins (GAPs) which bind to activated G proteins, stimulate their activity or
expedite GTP hydrolysis. When bound to GTP, KRAS can bind to cellular effector
molecules such as son of sevenless (SOS) complexed with adaptor proteins like
growth factor receptor-bound protein 2 (Grb2) to transmit signals from the cell
membrane to the nucleus. These signaling cascades are known to influence
cellular processes such as cell differentiation, proliferation, and apoptosis.
12

Importantly, the activation of KRAS is not just a single-step process but requires
correct interactions with effector and scaffolding proteins such as SHP-2 for proper
activation (34).
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Figure 1.1. The KRAS signaling cascade. Upon ligation of RTKs with soluble
growth factors or cytokines, the RTKs will trans-autophosphorylate allowing for
the recruitment of protein complexes (Grb2/SOS/SHP-2) to the cell membrane
which may then recruit additional proteins (KRAS) to allow for the initiation of
cell signaling cascades that control cell growth and survival.
Made with Biorender.com
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Upstream of Ras is a wide variety of membrane bound RTKs including but
not limited to EGFR, Her2, platelet derived growth factor receptor (PDGFR), ROS
proto-oncogene 1 (ROS1), ALK, VEGFR and others (35)(36)(37). Activation of
RTKs upstream of Ras occurs upon binding an appropriate ligand which are most
commonly growth factors like EGF or cytokines. Upon ligation, monomeric RTKs
will then dimerize and auto, or trans-autophosphorylate, tyrosine residues on their
cytoplasmic domains. The phosphorylated tyrosine residues then function as
binding sites for adaptor proteins such as SHP-2 and Grb2 which contain Src
homology 2 (SH2) or phosphotyrosine binding (PTB) domains. The adaptor
proteins may recruit additional scaffold or adaptor proteins such as the GEF SOS
to form complexes. The complexes can associate with membrane-bound KRAS
and catalyzes its transition to an active GTP-bound state. Once active, KRAS can
then bind to and activate additional downstream effector molecules to initiate signal
transduction pathways that control proliferation (Raf/MEK/ERK), apoptosis
(PI3K/Akt/mTOR), cytoskeletal reorganization (TIAM1/Rac/Rho), and cell cycle
progression (PLC/PKC) (37).

As stated above, in NSCLC mutations in the KRAS gene are common and
function to impair the ability of KRAS to revert to an inactive GDP-bound state. As
many as 30% of all NSCLC tumors harbor mutations in the KRAS gene and are
generally mutually exclusive from tumors driven by EGFR mutations. The
distribution of mutations in the Ras gene vary by cancer type and Ras isoform.
However, a vast majority of the mutations in the KRAS gene occur at the 12th
codon (83%) which encodes a glycine residue, followed by the 13th codon (14%)
which also encodes a glycine, and lastly the 61st codon (2%) which encodes
glutamine (38). Mutations at G12/G13 substantially reduce the GTPase activity of
KRAS which prevents its reversion to an inactive GDP-bound state. This then
results in the constitute activation of downstream pathways that drive cell growth
and survival. In NSCLC, the most common substitutions are KRASG12C, KRASG12V
(found most often in smokers) and KRASG12D all of which have been shown to have
varying effects on the activation levels of different downstream growth and survival
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pathways (39). Substitutions in codon 61 that change the polar uncharged amino
acid glutamine to charged residues such as histidine are thought to impair the
coordination and stabilization of GTP hydrolysis which catalyzes the return of
KRAS to an inactive GDP-bound state (40).

Therapeutic interventions for NSCLC

The treatment of NSCLC depends on the stage of the disease upon
diagnosis. For early-stage NSCLC (Ia to resectable IIIb) the primary treatment is
localized radiation therapy to reduce tumor mass followed by with surgery to resect
the tumor. As tumor stage progresses past Ia, chemotherapeutic agents such as
cisplatin, docetaxel, etoposide, and vinorelbine are used as neoadjuvant therapies
to increase the chances of a complete resection. For tumors that progress to nonresectable stage IIIb/IV, next-generation sequencing (NGS) is often applied to
determine the mutational profile of the tumor and direct the application of targeted
therapies. In the absence of actionable mutations, chemotherapy is often used as
palliative therapy (41).

In LUAD, targeted therapies are available for tumors which harbor
mutations in EGFR, ALK, or ROS1. First generation small molecule inhibitors of
EGFR such as erlotinib and gefitinib (also known as tyrosine kinase inhibitors, or
TKIs) bind to the intracellular tyrosine kinase domain of EGFR and prevent it from
phosphorylating substrate proteins. Additionally, monoclonal antibodies like
cetuximab have been used to bind to and inhibit EGFR signaling in colorectal and
head and neck cancers (42). Although first generation TKIs which bind to and
disrupt oncogenic EGFR signaling have demonstrated great clinical success,
acquired resistance to these therapies through mutations in the domains to which
the drugs bind has presented significant obstacles in their optimal application
(43)(44). Mutations such the T790M substitution, which arises from mutations in
exon 20 of the EGFR gene, alters the structure of the intracellular tyrosine kinase
domain of the protein and is able to overcome competitive small molecule inhibition
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by drastically increasing its affinity for ATP binding (45). This has prompted the
development of second and third line EGFR inhibitors such as the third generation
EGFR TKI Osimertinib, which has a higher affinity specifically towards the T790M
EGFR mutant (45).

While there exist targeted therapies against major LUAD oncogenes, direct
inhibition of the KRAS protein with small molecules has proven exceptionally
difficult, despite decades of research (46). Very recently, a small molecule inhibitor
of the KRAS G12C variant, AMG510, has shown promising results in early phase
clinical trials. Regardless, there remain no FDA-approved targeted therapies for
patients harboring KRAS mutations and thus therapies are limited to cytotoxic
chemotherapy. As a result of this unmet need, efforts have been made to find new
targets downstream of KRAS signaling that may serve as more suitable drug
targets to varying levels of success. Additionally, the use of ICIs in KRAS active
cancer offers a new targeted therapeutic avenue for patients with this type of
mutation.

1.3

IMMUNE CHECKPOINT INHIBTORS AND PD-L1

Monoclonal antibodies and the advent of Immune checkpoint inhibitors

Within the last decade, the emergence of a class of drugs known as immune
checkpoint inhibitors (ICIs) has had an extraordinary impact on the field of cancer
therapy. In 2011, the FDA approved the use of the first ICI, ipilimumab, for the
treatment of metastatic melanoma (47)(48). It did not take long for the potential
efficacy of this newly emerging branch of immunotherapy to be fully recognized
(49)(50). Within several years of this drugs approval, the development of
monoclonal antibodies was rapidly accelerated, amounting to the FDA approval of
the first drug ever given a ‘breakthrough therapy’ designation, obinutuzumab. The
impact of ICIs, especially for patients that until recently had no other treatment
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options, was so immense that the new ‘breakthrough therapy’ designation was
created to get ICIs to the bedsides of patients as quickly as possible.

While there are many proteins for which monoclonal antibody therapies
have been developed, by far the most effective are antibodies which target the
immune checkpoint proteins cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed death protein 1 (PD-1), and its ligand programmed death ligand 1
(PD-L1). These proteins serve a highly important biological function; to modulate
the activity and activation of T cells.

The revolutionary discovery of the CTLA-4 immune checkpoint pathway
occurred in the early 90s in the lab of James P. Allison when he observed that
CTLA-4 had the ability to reduce the action of activated T-cells. He soon developed
an antibody against CTLA-4 that could block its function by pharmacologically
inhibiting the endogenous inhibitor of immune cell activation. Pre-clinical animal
studies quickly confirmed his hypothesis with impressive results, though it wasn’t
until roughly a decade later in 2007 that phase 1 clinical trials of ipilimumab began
for the treatment of various kinds of treatment resistant cancer (51).

Around the same time as the discovery of CTLA-4, Tasuku Honjo made the
discovery of PD-1 and came to understand that it possessed immunomodulatory
capabilities like that of CTLA-4. PD-1 is another receptor expressed on the surface
of activated T-cells, and upon ligation to PD-L1, is internalized and through a
separate mechanism to CTLA-4 deactivates the T-cell. In 2014, the first
monoclonal antibody against PD-1, pembrolizumab, was approved by the FDA for
the treatment of metastatic melanoma. Soon after in 2015, it was approved for use
in patients with treatment resistant metastatic NSCLC, and whose tumors
expressed PD-L1.

While activation of both the CTLA-4 and PD-1/PD-L1 pathways results in
the deactivation of cytotoxic T-cells, there are some key differences in the
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mechanism by which they do so (51). PD-L1 is normally expressed on the surface
macrophages, T-cells, B-cells, and healthy epithelial cells in response to an
immune reaction and primarily functions as a mechanism for the immune system
to differentiate “self” from “non-self”. Upon ligation of PD-L1 to its receptor PD-1,
expressed on the surface of activated T-cells, the PD-1 receptor is internalized and
initiates a signaling cascade that results in the deactivation of the T-cell. What
makes this pathway so pivotally important in the context of cancer is the ability of
a tumor to aberrantly express PD-L1 on the cell surface, thus co-opting the
immunoregulatory function of PD-1 ligation and inappropriately deactivating
cytotoxic T-cells, often times to such an extent it leads to T-cell exhaustion.

CTLA-4 is a receptor expressed on the surface of activated T-cells that
competes with the CD28 receptor to bind to its ligand B7 which is expressed on
the surface of antigen presenting cells (APCs) (52). The relative expression levels
of CTLA-4 and CD28 are based on the activation level of the T-cell receptor (TCR)
via major histocompatibility complex (MHC) binding. A weak TCR stimulus causes
CD28:B7 binding to overcome CTLA-4:B7 binding and results in activation of
signaling cascades that promote T-cell proliferation, survival, and cytokine
production (53). When a strong TCR stimulus occurs, the inverse happens, and
there is a net negative effect on T-cell activation. The primary function of the CTLA4 pathway is to reduce T-cell activity in the interest of protecting healthy cells from
an overactive immune response, thus functioning as an “immune checkpoint” that
restrains immune cell activation. Importantly, the CTLA-4 pathway impacts the
earlier phases of immune activation by influencing immune cell proliferative
potential (54).

In contrast to the CTLA-4 pathway which produces its effects in the early
phases (i.e. priming phase) of immune activation, the PD-1/PD-L1 interaction
occurs in the later stages (i.e. effector phase) of T-cell activation by suppressing
activated, cytotoxic T-cells. Furthermore, CTLA-4 is primarily expressed on
regulatory T-cells, whereas PD-1 is expressed on other types of immune cells such
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as B-cells or myeloid cells. These two immune checkpoint pathways also differ in
the expression of their ligands, B7 and PD-L1. B7 is expressed by APCs which are
typically found within lymphatic tissues, as opposed to PD-L1 which can be
expressed upon a wide variety of peripheral and immune cells, and more
importantly, on many different types of tumors.

Monoclonal antibodies against PD-1 and PD-L1 have indeed demonstrated
clinical success across a variety of cancer types, specifically in advanced
melanoma and NSCLC. In 2015, results were published from the KEYNOTE-001
trial, a multicohort phase 1 study of pembrolizumab (brand name Keytruda) in
patients with metastatic carcinoma, melanoma, or NSCLC carcinoma (55).
Pembrolizumab demonstrated tolerable antitumor activity in NSCLC patients
regardless of prior treatment status, and in 2017, the investigators reported a
median overall survival (OS) time of 22.1 months (56). Very importantly, these
patients all had a PD-L1 tumor proportion score (TPS) of at least 50% (determined
by immunohistochemistry (IHC) staining), suggesting that tumors expressing the
highest levels of PD-L1 may respond better to PD-1/PD-L1 inhibition than tumors
with lower PD-L1 expression (56). In 2019, 5-year results were reported that
showed OS rates of 23.2% for treatment-naïve patients and 15.5% for previously
treated patients (57). The significance of these improvements to long term survival
cannot be overstated when compared to the historic 5-year OS rate of 5.5% (56).
Additional KEYNOTE trials have shown repeatable clinical value of PD-1/PD-L1
inhibition in NSCLC and the relevance of a PD-L1 TPS ≥ 50% (58)(59)(60).
Importantly, KEYNOTE trials 42 and 189, demonstrated the value of these targeted
therapies in patient tumors not harboring mutations in EGFR or ALK (61)(62).
Given the mutually exclusive nature of EGFR, KRAS, and ALK mutations, these
findings support the notion that patients with KRAS-mutant tumors (for whom there
exist no targeted therapies) are poised to greatly benefit from PD-1/PD-L1
blockade (63)(64).
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Although the results of these clinical trials provide the foundation for a
promising future for drugs which inhibit PD-1 or PD-L1, there remain significant
limitations to these therapies that curtail their optimal application. One such
limitation is the occurrence of significant adverse reactions that can negatively
impact nearly every major organ system (65). These treatments also face a major
challenge in feasibility; the price of therapy often exceeds $100,000 over the
course of treatment, thus greatly limiting their use only to patients able to afford it.
Further compounding these issues is the low rate of response to PD-1/PD-L1
blockade (20-30% overall response rate (ORR) in solid tumors) (66). The objective
response rate to PD-1/PD-L1 blockade is also known to vary by tumor type, with
melanoma typically demonstrating the most consistent response (30-45%), trailed
by NSCLC (15-20%) (67)(68). As demonstrated by the KEYNOTE trials, NSCLC
patients with a high PD-L1 TPS (≥50%) responded better to therapy than those
with a TPS below 50%. However, a high PD-L1 TPS does not necessitate
response to therapy; clinical studies have shown that even in NSCLC patients with
high PD-L1 expression, as many as half still did not respond to the PD-1 inhibitor
pembrolizumab (69). Conversely, the lack of PD-L1 expression does not mean a
patient will not response to therapy. In certain cases, the response rates between
those with and without tumoral PD-L1 expression remain relatively similar (70).
The lack of understanding as to why some patients without tumoral PD-L1
expression still respond to PD-1/PD-L1 inhibition warrants further investigation into
the mechanisms malignant cells apply to aberrantly express PD-L1 and evade
immune system detection.

It is apparent that the expression of PD-L1 on a patient tumor is of clinical
significance, though it has shown to be insufficient as a sole indicator of response
to PD-L1 blockade. This suggests that a more sophisticated metric than the mere
quantity of PD-L1 expressing cells is a necessary prerequisite to the complete
utilization of PD-L1 expression as a prognostic indicator. As such, many attempts
have been made to identify biomarkers of response to PD-1/PD-L1 blockade to
replace or supplement tumoral PD-L1 expression. For example, tumor mutational
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burden (TMB) is a measure of the quantity of somatic non-synonymous coding
mutations in a tumor. Tumors with a high TMB (20 or more mutations per
megabase) express a greater number of mutated proteins resulting in heightened
immunogenicity through the increased likelihood of neoantigens being recognized
by the immune system. Another proposed biomarker, microsatellite instability
(MSI), reflects changes in the number of nucleotides in DNA elements composed
of repeated motifs (71). MSI quantifies the number of times DNA mismatch repair
systems fail to correct errors and is indicative of the levels of genetic instability
within a tumor. Though it is true that this instability is often detrimental to an
individual cells growth and survival, when this instability is extrapolated to a larger
population of cells rapidly replicating, this instability eventually results in
advantageous mutations that allow for continued or expedited tumor growth. Both
TMB and MSI have been able to provide prognostic value in differing cancer
subtypes, but they are inferior in their accuracy compared with PD-L1 TPS. The
most effective prognostic indicator response to PD-1/PD-L1 blockade may be a
combination of these independent biomarkers (72).

Given the importance of PD-L1 expression (especially when a tumors TPS
is ≥50%) in the application of ICIs in NSCLC, a comprehensive understanding of
the mechanisms governing PD-L1 expression is vital. PD-L1 expression can vary
greatly not only between individual NSCLC tumors, but also within different regions
of the tumor itself. This heterogeneity has been hypothesized to be a major factor
that cripples the prognostic clinical value of PD-L1 TPS. The factors regulating PDL1 expression are not yet fully understood, however mechanisms which have been
investigated thus far can be grouped by transcriptional and post-transcriptional
control.

Intrinsic factors which regulate genetic and epigenetic alterations have been
demonstrated to impact the expression of PD-L1. Methylation of the CD274
promoter has been shown to reduce PD-L1 transcriptional activity in NSCLC, and
the expression of histone deacetylase has been correlated with PD-L1 expression
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as well (73). Further transcriptional regulation of PD-L1 expression is augmented
by the activity of signal transduction pathways such as RAS/Raf/ERK, EGFR,
PI3K/Akt/mTOR, and tumor suppressing pathways involving TP53 or STK11 all of
which may influence PD-L1 expression to some extent (74)(75)(76). Extrinsic
factors such as cytokines, specifically molecules such as IFN- γ and IL-6, are
known to induce the expression of PD-L1 in many different types of cancers and
immune cells alike (77). Growth factors that stimulate the above-mentioned
pathways can also induce PD-L1 transcriptional activity (78). DNA damaging
agents and angiogenesis/hypoxia may also influence the transcriptional activation
of PD-L1 (79). Once transcribed into mRNA, a variety of different miRNAs can
target the CD274 transcript to fine tune its translation into protein (80)(81). The
stability of CD274 mRNA can also be impacted by alterations to the 3’-UTR of the
transcript, and oncogenic Ras signaling has also been shown to influence CD274
mRNA stability (82)(83). Additionally, post translational modifications to the PD-L1
protein
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PD-L1

and

expression
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metabolism

(84)(85)(86).

1.4

PHOSPHATASES, KINASES, AND SHP-2

Protein Phosphorylation
Protein phosphorylation is a major modality by which protein function and
activity is controlled. Phosphorylation is a reversible post-translational modification
(PTM) of eukaryotic proteins carried out by kinase enzymes. Furthermore, protein
phosphorylation is an essential component of various signal transduction
pathways that relate to the development and progression of cancer. The human
genome contains at least 518 protein kinases which may phosphorylate as many
as 70% of all known human proteins (87). The possibility that proteins may become
post-translationally phosphorylated was discovered in the early 1900s; however, it
wasn’t until half a century later that protein phosphorylation was described as an
23

enzymatic process. This discovery stirred further interest into researching the
biological relevance of kinases and their importance to cellular signaling pathways.
In 1992, Edmon Fischer and Edwin Krebs were awarded the Nobel prize for their
discoveries concerning reversible protein phosphorylation (88). Since then, many
research groups have devoted their efforts to begin completely characterizing the
human kinome (89).

In eukaryotes, protein phosphorylation is carried out by protein kinases which
attach a negatively charged hydrophilic phosphate (PO4-) group from adenosine
triphosphate (ATP) to either serine, threonine, or tyrosine residues. The addition
of a phosphate group to a protein likely changes its structure, function, localization,
or ability to interact with other proteins. The phosphorylation of a protein can result
in a vast array of changes to its function, and the extent of phosphorylation to any
specific protein has a unique impact on the cellular processes in which it is
involved. For example, the tumor suppressor protein p53 can be phosphorylated
on serine residues following DNA damage which influences its ability to bind to
DNA and function as a transcription factor. In the case of PD-L1, serine/threonine
phosphorylation at T180 or S184 increases its binding affinity to E3 ligases and
results in its degradation (16).

Kinases

While there are only three (major) amino acids that become phosphorylated,
the kinases responsible for such modifications are specific to either Ser/Thr or Tyr,
and also highly specific for their unique protein substrates. The phosphorylation of
serine and threonine residues is typically carried out by dual-specificity kinases
that have the ability to add a phosphate group to either amino acid (90).
Phosphorylation of tyrosine residues is carried out by tyrosine kinases, and a very
small family of non-canonical kinases can phosphorylate both Ser/Thr or Tyr
residues. Of all known phosphorylation events in the human kinome, a vast
majority (95%) are the phosphorylation of serine residues, followed by 3-4% are
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that of threonine, and less than 1% tyrosine (90). Importantly, protein
phosphorylation plays a considerable role in essential signal transduction
pathways that regulate processes such as growth, survival, and cell division. Thus,
in cancer, kinase activity is often deregulated resulting in the constitutive activation
of pathways that regulate cell growth and survival. Given the wide array of known
kinases and the multifaceted functions they carry out, the dysregulation of kinase
activity within a tumor does not necessarily mean that all kinases are oncogenes,
and that it must be an increase in kinase activity that results in a tumor promoting
phenotype (91).

Despite tyrosine phosphorylation events being rare relative to that of serine
and threonine, their relevance to pathways often deregulated in cancer is
substantial. Receptor tyrosine kinases (RTKs) are transmembrane bound
enzymes that selectively phosphorylate tyrosine residues upon ligation to
extracellular signal molecules such as growth factors or cytokines. Upon ligation,
monomeric RTKs will dimerize and trans-autophosphorylate their cytoplasmic
kinase domains resulting in the recruitment of protein complexes which initiate a
wide array of signal transduction pathways (34)(35). The largest number of known
oncogenes belongs to the family of tyrosine kinases (9). As such, therapeutic
strategies which impede deregulated tyrosine phosphorylation are highly pertinent
to the treatment of cancer. Tyrosine kinase inhibitors (TKIs) have become some of
the most effective targeted therapies for many different cancer types, but
especially NSCLC. There have been multiple generations of TKIs that inhibit EGFR
activity, greatly stunting the progression of cancers which are dependent on EGFR
for growth (92). The clinical success of TKIs provides a logical foundation for the
development of drugs which target tyrosine phosphatases that function as negative
regulators of these same pathways.

Phosphatases
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Protein phosphatases function not only to help maintain and negatively
regulate the careful balance of protein phosphorylation within cell signaling
cascades, but to also participate in articulating the precise and structured
sequence of such phosphorylation events (93). It is important to note that
compared to the >500 known kinases (and 90 known tyrosine kinases) encoded
within the human genome there are only roughly 200 phosphatases, 38 of which
are tyrosine specific phosphatases (PTPs) (94). In the early 21st century, scientific
interest was heavily focused upon protein kinases. However, in the past decade,
the importance of phosphatases as more than just non-specific housekeeping
enzymes has gained appreciation.

Given the well characterized importance of tyrosine kinases in oncogenic cell
signaling, it is logical that negative regulators of the same processes should be of
equal importance. Although, generally, the phosphorylation of tyrosine resides
results in increased protein activity, this is not always the case, and so maintaining
the balance of Tyr phosphorylation can have varying effects on protein activity.
Understanding the general principle that phosphorylation of a protein increases its
activity, this would lead one to believe that PTPs should function as tumor
suppressors in an inverse manner to tyrosine kinases. However, though many
PTPs do in fact negatively regulate cell growth, migration, and invasion, a number
of PTPs have demonstrated tumor promoting properties which often differ based
upon the unique PTP as well as the type of cancer in which it is expressed (95)(96).
For example, Receptor-type tyrosine-protein phosphatase gamma (PTPRG) has
been shown to possess tumor suppressive properties in ovarian and breast cancer
(96). Several phosphatases of regenerating liver (PRL) have been reported to have
tumor promoting properties, and their overexpression, as is such in the case of
PRL3 which is overexpressed in metastatic colorectal cancer, but not in normal or
early-stage cancer tissue (97). It is also thought to contribute to the development
of lung and liver metastasis (98). Given the wide range of PTP activity on tumor
initiation and progression, further interrogation into the role of PTPs in cancer may
result in substantial clinical benefit.
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Despite recent revelations that PTPs may serve as suitable drug targets in
cancer, there have been challenges in developing small molecule catalytic
inhibitors against PTPs as a result of their promiscuous nature with regard to
protein substrates (99). However, the development of allosteric inhibitors that
possess higher specificity for phosphatases relevant to oncogenesis and tumor
progression are beginning to show clinical promise, thus warranting further
investigation into the biology that underpins PTP function with tumor cells (100).
One such phosphatase that has been identified as a critical regulator of oncogenic
signaling pathways (such as the KRAS pathway) is the tyrosine phosphatase SHP2.

SHP-2

The non-receptor tyrosine phosphatase, Src homology region 2 domaincontaining, phosphatase-2 (SHP-2) encoded by the PTPN11 gene, is ubiquitously
expressed in a variety of mammalian cells and has gained attention as a
therapeutic target in recent years. SHP-2 is expressed in both NSCLC patient
tumors and cell lines. SHP-2 has three major structural domains; a catalytic protein
tyrosine phosphatase (PTP) domain on the C-terminal region and two neighboring
Src homology region 2 (SH2) domains on the N-terminal region (101). The SH2
domains function to bind to phosphorylated tyrosine residues on protein
substrates, but also possess unique functions that modulate the various activities
of SHP-2 itself. In its basal inactive state, the N-SH2 domain binds to and inhibits
PTP activity or binds to phosphoprotein substrates, whereas the C-SH2 domain
contributes to binding energy and substrate specificity (102). The activity of SHP2 is controlled through autoinhibitory interactions between the catalytic PTP
domain and the N-SH2 domain. The regulation of this inhibitory state is governed
through conformational changes induced from binding with protein substrates,
mediated through the phosphorylation of two tyrosine residues (Y542 and Y580)
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located on its c-terminal domain (CTD) which influence its affinity to protein
substrates.
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Figure 1.2. Structural conformations of SHP-2. When in an inactive
state, the N-terminal SH2 domain will fold back on the catalytic
phosphatase domain, preventing phosphatase activity (top). Once activated
(through Tyr phosphorylation on its C-terminal domain at Y542 or Y580, or
by binding to protein substrates) the N-SH2 domain releases from the PTP
domain, allowing phosphatase activity (bottom). Made with Biorender.com
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Figure 1.3 The activities of SHP-2. Expanded diagram of SHP-2’s
involvement within the KRAS signaling cascade, as well as the JAK/STAT and
PI3K/Akt pathways. SHP-2 has been shown to both positively and negatively
regulate STAT signaling through its catalytic phosphatase activities.
Additionally, SHP-2 has been shown to be involved in anti-apoptotic signaling
by suppressing caspase-3 mediated apoptosis (104).
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SHP-2 has been implicated in numerous pathways relevant to cancer, and
the precise nature in which it impacts these pathways is both highly complex and
context specific. It has been shown to be a negative regulator of the Jak/STAT
pathway by dephosphorylating Tyr701 of STAT1 in response to interferon
stimulation. Conversely, SHP-2 can also positively regulate Jak/STAT signaling by
dephosphorylating Tyr1007 of Jak2, reducing its ability to form a degradation
inducing complex with Socs1, thus preventing Jak2 turnover (103). Additionally,
SHP-2 catalytic activity is required for proper regulation of the PI3K/Akt survival
pathway (104). However, it is not only the catalytic PTP activity of SHP-2 which is
responsible for its signal transducing capabilities. In immune cells, ligation of the
PD-1 receptor results in SHP-2 mediated receptor dimerization and internalization
which occurs irrespective of SHP-2s PTP activity (105). Indeed, SHP-2 serves a
variety of functions in oncogenic signaling pathways, though not to be
overshadowed is its critical role in mediating KRAS signaling events. Several
groups have demonstrated the importance of SHP-2 within the RAS/Raf/ERK
signaling cascade, even going so far as to insinuate SHP-2 as a critical regulator
of KRAS-signaling in NSCLC (106). Furthermore, it has been shown that KRASmutant NSCLC depends on SHP-2 for carcinogenesis, though ablation of SHP-2
activity or expression was only sufficient to delay tumor progression, not reverse it
(107).

Despite the known importance of SHP-2 in this oncogenic signaling pathway,
whether SHP-2 is a tumor suppressing or promoting protein remains unclear and
may depend on the context in which it is expressed. SHP-2 has displayed tumor
suppressing activities in hepatocellular carcinoma and has been shown to
suppress oncogenesis by dephosphorylating Ras in glioblastoma (108). Outside
the realm of cancer, mutations that impact the catalytic activity of SHP-2 are linked
to diseases such as Noonan syndrome (NS) and Noonan syndrome with multiple
lentigines (NSML). These diseases can cause a wide variety of developmental
defects that vary from one individual to another and can change over the course
of an affected individual’s lifespan (109). This demonstrates that the impact of
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SHP-2 expression bears great relevance to the molecular context in which it is
expressed. As it stands, further understanding of the impact of SHP-2 expression
within the context of a lung tumor and how that relates to the regulation of
oncogenic lies the potential for the development of new therapies that diminish
SHP-2 activity or expression. However, until we are able to better understand the
complex nature of phosphatases (and SHP-2 specifically) involvement in
oncogenic signaling pathways, we remain limited in our ability to create efficacious
therapies that synergize with currently available treatments, such as TKIs and
immunotherapies.

1.5

PROJECT OVERVIEW
The aim of the work described herein was to combine the application of in

vitro biochemical experimentation with analysis of real-world, publicly available
clinicogenomic information to uncover a mechanism by which SHP-2 controls the
regulation of PD-L1 in KRAS active non-small cell lung cancer (NSCLC). It has
been a long-standing goal of this laboratory to harness the power of
pharmacogenomic data to improve the personalization of therapy for NSCLC
patients. While the scope of the presented work resides primarily within the realm
of foundational biology, its reach expands into the domain of clinical practice by
explicating the underlying mechanisms that influence the efficacy and application
of existing and emerging cancer therapies.

As the use of immune checkpoint inhibitors (ICIs) rapidly transitioned from
bench to bedside within the past decade, the accumulation of clinical information
has begun to reveal the flaws preventing optimal utilization of these therapies. To
date, the ability to predict which patients will elicit a response to immune checkpoint
inhibition remains strikingly poor and has been estimated to lead to responses in
less than 13% of patients with cancer in the US (110). Importantly, the benefit of
ICI treatment in responding NSCLC patients exceeds that of other cancers, further
demanding improved methods to predict responsive patients in this type of cancer
(110). Among the methods that have been approved to predict which patients will
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respond to immune checkpoint inhibition based upon the stage of the disease, the
most impactful has been tumoral expression of PD-L1, specifically tumors with
>50% total PD-L1 expression. It is therefore important to gain a complete
understanding of the factors which govern PD-L1 expression in NSCLC. The
mechanisms governing the expression of PD-L1 in tumor cells are diverse and
continue to grow in number adding complexity to the combined impact of their
actions. Resulting from this complexity is the discovery of drug targets which may
synergize with PD-L1 inhibition. These combinations may have considerable
clinical value, especially in patients harboring activating KRAS mutations who have
few targeted therapeutic options.

I hypothesized that the tyrosine phosphatase, SHP-2, is capable of regulating
PD-L1 expression, specifically in KRAS-active NSCLC. To address this hypothesis,
I analyzed publicly available protein and gene expression data collected from
NSCLC patients to investigate correlations in both the expression and activity
of SHP-2 and the expression of PD-L1. I then acquired data sets from two
additional studies to further interrogate the relationship between SHP-2 and
PD-L1 expression and to determine whether SHP-2 expression correlates
with response to immune checkpoint inhibition (Chapter 2). Second, I
conducted in vitro biochemical analyses to examine the expression and
activity of SHP-2 in KRAS active NSCLC cell lines and measure the impact on
PD-L1 expression (Chapter 3). Finally, I utilized biochemical and proteomic
techniques to uncover novel protein-protein interactions using SHP-2 as bait
to define the partners with whom SHP-2 interacts as a means to discover the
mechanism(s) by which SHP-2 governs PD-L1 expression in KRAS active
NSCLC.
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CHAPTER 2.

2.1

Overview
The identification of novel therapies, new strategies for combination of

therapies, and repurposing of drugs approved for other indications are all important
for continued progress in the fight against lung cancers (22). Perhaps the most
significant advance in therapy for many cancer types was the entry of immune
checkpoint inhibitors (ICI) as a standard of care therapy for melanomas in 2014
(111). For non-small cell lung cancers (NSCLC), specifically those without
targetable mutations in epidermal growth factor receptor (EGFR) or anaplastic
lymphoma kinase (ALK), ICIs that target programmed cell death 1 (PD-1) or
programmed death ligand 1 (PD-L1), have revolutionized cancer therapy even
though response rates are relatively low (112).

Both pembrolizumab and atezolizumab, PD-1 and PD-L1 inhibitors
respectively, are approved ICI for frontline lung adenocarcinoma therapy for
patients with high levels of PD-L1 expression on tumor cells (113). Durvalumab,
an anti-PD-1 agent, is approved as maintenance therapy (114). Decisions to
implement ICI therapy are often dependent on the PD-L1 tumor proportion score
(TPS) using evidence from the KEYNOTE-024 and -042 trials (115) (116).
Importantly, PD-L1 expression may not be the optimal biomarker of response as
suggested in pivotal clinical studies (e.g. KEYNOTE and OAK trials), but it is clear
that patients with high levels of tumoral PD-L1 are likely to experience a robust
response to checkpoint inhibition (117). While many research groups have
searched for improved biomarkers of response for checkpoint inhibitors, others
have focused on identification of therapies that might be combined with ICI to
improve patient outcomes (118).

I found that inhibition of the tyrosine phosphatase, SHP-2, increased gene
and cell surface protein expression of PD-L1 in KRAS-active NSCLC cell lines.

PD-L1 is normally expressed on the surface of antigen presenting cells while PD1 is expressed on T cells. It is the abnormal expression of PD-L1 on tumor cells,
and the subsequent engagement with PD-1 on T cells, that causes tumors to be
masked from an immune response (119). Inhibiting this interaction with antibodies
against either PD-1 or PD-L1 can release a potent immune response toward the
tumor. I hypothesized that because SHP-2 provides some level of control of
expression of PD-L1 on NSCLC cells that inhibition of SHP-2 would increase PDL1 expression and synergize with ICI therapy. Supportive of my hypothesis is
recently published data by Chen and colleagues who showed in a NSCLC model
system that combined SHP-2 and PD-L1 inhibition, with accompanying radiation,
can overcome resistance to PD-1 inhibitors (120). Other groups have suggested
that SHP-2 activity maybe more important in T cells, that infiltrate the tumor, to
carry out signaling events downstream of PD-1 stimulation (121). Uncovering the
precise mechanism of SHP-2 action on PD-L1 expression consumes many
research groups, the model systems are expensive, and experimental time is long
to get a drug to the clinic.

With these obstacles in mind, I chose to go to real world data to determine
whether SHP-2 activity is related to PD-L1 expression and thereby focus my
research efforts. I took advantage of three publicly available data sets to assess
whether wet lab experimentation to determine if exploring the combination of ICI
and SHP-2 inhibition would likely have clinical impact. First, The Cancer Genome
Atlas (TCGA), now known as the NCI Genetic Data Portal (NCI-GDC), holds wellannotated expression and functional proteomic data (The Cancer Proteome Atlas
(TCPA)) for patient tumors. However, most samples were collected prior to FDA
approvals for ICI therapy, so no response data for ICI treatment is available
(https://portal.gdc.cancer.gov/projects/TCGA-LUAD).

Unfortunately,

larger,

industry-sponsored trials evaluating the clinical space for PD-1 and PD-L1
inhibitors are still open (e.g. KEYNOTE and OAK), and full genomic and patient
response datasets are not yet published. Therefore, in order to link expression of
SHP-2 and PD-L1 with response to ICI, I uncovered two small studies: one in
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NSCLC and one in melanoma patients (122) (123). Using real world data from the
three studies identified, the hypothesis that inhibition of SHP-2 activity is likely to
improve response to PD-L1/PD-1 inhibitors justifies wet-lab characterization of the
mechanism(s) of activity.

2.2

Methods

TCPA and GDC analysis of PTPN11 and CD274 expression
TCPA (https://tcpaportal.org/tcpa/index.html), a functional proteomics
database which contains reverse phase protein array (RPPA) data from a wide
variety of clinical tumor samples was used to identify a lung adenocarcinoma
(TCGA-LUAD-L4) dataset containing RPPA data from 362 individual patient
samples. These data contain quantitative protein expression levels of 237 unique
proteins for each subject. From the TCPA data, SHP-2_pY542, the
phosphorylated and active form of SHP-2 and PD-L1 were compared from 362
patient tumors for relative protein expression levels using a two-tailed, nonparametric Spearman correlation analysis with 95% confidence intervals.
Corresponding RNA-sequencing data was acquired from TCGA, now NCI-GDC
(https://portal.gdc.cancer.gov), for the genes PTPN11 (SHP-2) and CD274 (PDL1). RNA sequencing data that matched the previously-queried RPPA data for
the 362 patient using identifiers linking the TCPA database and the
corresponding RNA-sequencing data in GDC. I utilized fragments per kilobaseupper quartile (FPKM-UQ) values. The FKPM-UQ values for the genes PTPN11
and CD274 for each tumor were analyzed by Spearman correlation analysis as
previously described.

I conducted the same correlation analysis between PTPN11 and CD274
on the FPKM-UQ values for the full TCGA-LUAD dataset of 585 tumor samples.
The tumors were sub-grouped using information on KRAS variants (KRASmutants n=99, KRAS-WT n=486) known to be active and performed the same
analysis of PTPN11 and CD274 mRNA levels.
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I then identified another data warehouse (cBioPortal: cbioportal.org) that
that contains gene expression data from clinical cancer studies. Specifically, we
located a study sought to characterize the genomic landscape of lung
adenocarcinomas in East Asians (197). This study contains RNAseq data for 169
patients, from which I conducted a two-tailed, non-parametric Spearman
correlation analysis with 95% confidence intervals between PTPN11 and CD274
mRNA levels (normalization method: z-score).

Last, I selected 10 proteins which I hypothesized to be involved in the
regulation of PD-L1 expression from the mass spectrometry analysis of proteins
that co-immunoprecipitated with SHP-2 in Chapter 4. For each of the 10 proteins,
FPKM-UQ values from the full TCGA-LUAD dataset (n=585) were subjected to
the same correlation analysis as previous described between each of the 10
genes and CD274 and PTPN11.

PTPN11 and CD274 expression compared with resistance to ICI in
melanoma tumors
Single-cell RNA-sequencing (scRNA-seq) data from 31 melanoma tumors
that were 1) not treated with ICIs or 2) became resistant to ICIs following treatment
was acquired from the Gene Expression Omnibus (GEO). The R-studio
Bioconductor GEOquery package was used to capture raw scRNA-seq transcript
per mission values, cell counts, and annotations from this study (GSE115978).
TPM values were calculated and annotated by the authors as described in JerbyAmon L., et al (122) and then imported into Graphpad Prism for statistical
analyses.

I established that scRNA-seq reads were available for several cell types,
including immune cell types and malignant cells in tumors that were not treated
with ICI (n=15). From these data, only single cells that were determined to be
malignant melanoma cells by flow cytometry were selected for study. Of the 15
untreated tumors, the analysis was arbitrarily narrowed to include patient tumors
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that had scRNA-seq data for at least 30 unique malignant cells (n=6). To identify
proportion of single cells in an individual tumor that expressed PTPN11, the
percentage of cells with non-zero TPM scores for PTPN11 for each tumor was
calculated. The mean TPM and standard deviation values for PTPN11 and CD274
for all single malignant cells in these six tumors were then calculated.

Similarly, tumors (n=15) that had acquired resistance to ICI therapy were
processed to include only tumors (n=6) with at least 30 unique malignant cells. I
applied the methods used above to calculate the proportion of single cells
expressing PTPN11 for each tumor, and the mean TPM values with standard
deviation for PTPN11 and CD274 when the single cells of all six tumors were
evaluated together. These values were then used to assess any correlations
between PTPN11 and CD274 expression and resistance to ICI therapy.

PTPN11 and CD274 expression compare with response to ICI in NSCLC
tumors
A study was identified for which expression data was evaluable that
analyzed immune signatures predictive of response to anti-PD-1 inhibitors in
NSCLC (123). The dataset contains RNA-sequencing and clinical response data
for 21 NSCLC patients treated with single agent anti-PD-1 therapies. The R-studio
Bioconductor GEOquery package was used to capture raw RNA-sequencing TPM
values from this study (GSE136961). Patients who demonstrated progression of
disease or stable disease that lasted less than 24 weeks were deemed by the
authors to have no durable clinical benefit (DCB) to anti-PD-1 therapy. Patients
showing partial or complete response by Response Evaluation Criteria in Solid
Tumor (RECIST) v1.1 or stable disease for more than 24 weeks were defined as
receiving DCB.

Of the 21 NSCLC patients in this study, nine demonstrated a DCB to ICI
therapy and twelve showed no DCB. I binned the data by DCB status and then
averaged all TPM values for PTPN11 and CD274 for each patient tumor to
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generate the mean TPM score and standard deviation for each group. An outlier
analysis was conducted on the PTPN11 TPM data for both DCB and no-DCB
groups. Outliers were determined by the 1.5 interquartile range (IQR) method
which adds 1.5 times the IQR to the third quartile and excludes data points that fall
above that value and subtracts 1.5 times the IQR from the first quartile and
excludes data points that fall below that value.

2.3

Results

Phosphorylated SHP-2 correlates with the loss of PD-L1 expression in lung
adenocarcinomas

First, protein array data from TCPA LUAD-L4 dataset (n = 362) was
analyzed to assess correlations between the active, phosphorylated form of
SHP-2 and PD-L1. The analysis revealed that levels of SHP-2_pY542 show a
significant negative correlation with PD-L1 expression (r = -0.157, p-value =
0.0028) in these subjects, suggesting that inhibition of SHP-2 activity may
increase PD-L1 protein expression (Figure 2.1A and Figure 2.2A).

Next, to better understand the relationship between expression of SHP-2
(PTPN11) and PD-L1 (CD274) mRNA in these patient tumors, I analyzed
corresponding RNA-sequencing data (n=362) from the NCI-GDC. In this
database, the full TCGA LUAD dataset contained 585 tumor samples, but the
TCPA data does not contain complete coverage of the samples. Interestingly,
analysis of the matched data did not reveal a significant correlation (p-value =
0.3488) between PTPN11 and CD274 mRNA expression levels (Figure 2.1B).
Following this observation, I wanted to know if any relationship between PTPN11
and CD274 expression was found using the entire TCGA-LUAD RNAsequencing dataset. I found a modest but significant positive correlation existed
(r = 0.095, p-value = 0.0211) between PTPN11 and CD274 mRNA levels (Figure
1C). Tumors from this dataset were then sub-grouped by KRAS variants known
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to be either constitutively active or KRAS-wildtype, I uncovered no significant
relationships between PTPN11 and CD274 mRNA levels regardless of KRAS
status.
Extending my observations from the aforementioned data that suggest a
relationship between SHP-2 activity and PD-L1 expression, I identified another
data warehouse (cBioPortal: cbioportal.org) that contains gene expression data
from clinical cancer studies. The analysis revealed a positive (r = 0.267) and
significant (p-value = 0.0005***) correlation between PTPN11 and CD274 mRNA,
again suggesting that SHP-2 and PD-L1 protein are co-expressed in LUAD
tumors (Figure 2.1D). Together, these TCPA and RNA seq data suggest that
SHP-2 and PD-L1 protein are co-expressed in LUAD tumor tissue and that
activation of SHP-2, not simply expression, may control levels of PD-L1.
However, without knowing the expression levels of inactive SHP-2, we cannot
state with certainty that SHP-2 activity is the primary role by which SHP-2
regulates PD-L1 expression.

PTPN11 mRNA expression weakly associates with reduced CD274 mRNA
expression in melanoma tumors

Having established a correlation between tumoral SHP-2 activity and PDL1 expression, but not corresponding gene expression levels in lung
adenocarcinomas, I sought to understand whether PTPN11 and CD274
expression levels associate with response of patient tumors treated with ICIs. A
study was identified (Jerby-Amon L., et al. 2018) that analyzed scRNA-seq data
from melanoma tumors that were either treatment naive, or that had become
resistant to ICIs following treatment, and the authors of the study were interested
in characteristics of the melanoma cells that lead to immune evasion (122). Using
the expression data from this study, I sought to answer two main questions: 1)
does PTPN11 mRNA expression correlate with CD274 mRNA levels and 2) does
PTPN11 expression correlate with poor response to PD-1 inhibition? The workflow
scheme for the analysis is found in Figure 2.2B.
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To address the first question, the tumors were identified that were not
treated with ICI (n=15). The analysis focused on only melanoma tumors (n=6)
which had at least 30 malignant cell TPM reads resulting in a mean of 108 (s.d.
91-487) single cells per tumor. The proportion of cells which had non-zero TPM
values for PTPN11 was then calculated, revealing six untreated tumors (Mel71,
Mel79, Mel103, Mel80, Mel81, Mel89) that demonstrated ≥50% of single malignant
cells (mean= 69; range= 50-83%) that expressed PTPN11. Similar to the
TCPA/NCI-GDC analysis, I observed that elevated expression of PTPN11
associated with lower expression of CD274 in treatment naïve tumors.

Finally, I wanted to understand the relationship of PTPN11 and CD274
expression and response to ICI therapy. Patient tumors with acquired resistance
to therapy (n=15) were used to determine whether the relative levels of PTPN11
and CD274 were different from the treatment-naïve tumors. Again, these data were
processed to include only tumors with at least 30 malignant cells (n=6) and resulted
in a mean of 79 single cells (range 96-169) per tumor. The six ICI resistant tumors
(Mel78, Mel88, Mel98, Mel102, Mel110, Mel94) showed ≥50% single malignant
cells (mean=67; s.d.=57-82%) expressed PTPN11, with mean/standard deviation
TPM values for PTPN11 (mean=1.29; s.d.=0.12) and CD274 (mean=0.09;
s.d.=0.06). Here, similar expression patterns of PTPN11 and CD274 were
observed compared with treatment-naive tumors, and again CD274 levels remain
low when PTPN11 is expressed. Importantly, I did not observe any relationship
between PTPN11 or CD274 expression and acquired resistance to ICI in this
dataset.

CD274 mRNA expression associated with response to ICI in NSCLC tumors

Using the data from the next study (Hwang, et al. 2020), I asked whether
expression of PTPN11 and CD274 mRNA associates with response to ICI therapy
in NSCLC (123). The investigators in this report aimed to find immune signatures
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predictive of response to anti-PD-1 inhibitors in NSCLC. I utilized the gene
expression data to sort the 21 patient tumors to two groups based upon their DCB
status, resulting in nine patients who demonstrated DCB and twelve patients who
did not.

After calculating average TPM values for PTPN11 and CD274 and
excluding outlying tumors, the analysis revealed no significant difference in the
expression of PTPN11 mRNA between subjects with DCB from those that did not
respond to anti-PD-1 therapy. Specifically, the mean PTPN11 TPM score for DCB
was 576.15 with s.d.=281.78 and for no DCB (mean=487.73 with s.d.=361.24)
(Figure 2.3A). Importantly, the mean expression of CD274 mRNA was nearly 3fold higher in patients who responded to therapy (mean=151.16, s.d.=198.33)
compared to those who did not (mean=61.96, s.d.=64.54) (Figure 2.3B). Together,
these data showed that PTPN11 gene expression does not associate with CD274
expression or response therapy in NSCLC patients. These findings are consistent
with the results from the first study that suggested that SHP-2 activity, not
expression, correlates with PD-L1 expression. In contrast, these data suggest a
positive relationship between PD-L1 expression and response to ICI which was
not observed in the melanoma study.

Proteins that interact in vivo with SHP-2 significantly correlate with both
PTPN11 and CD274 mRNA expression in lung adenocarcinomas

In Chapter 4, mass spectrometry analysis was performed to determine the
identity of proteins that co-precipitated with SHP-2 to investigate the proteinprotein interactions in which SHP-2 is involved. I hypothesized that these
proteins may assist SHP-2 with maintenance of PD-L1 expression. To
understand whether these proteins are co-expressed with SHP-2 in patient
tumors and not just in cell culture, I applied the same analysis of the TCPA and
GDC data sets to further inform my wet-lab research.
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First, I searched for RPPA data from TCPA for the top 10 scoring proteins
from that analysis, presented in Table 2.1A. Unfortunately, no protein array data
were available for any of my 10 proteins of interest. I then evaluated the RNAseq data in GDC to identify gene expression data for these proteins in order to
correlate expression with that of PTPN11 mRNA. Of the expression of 10 genes
analyzed against PTPN11 in the full TCGA-LUAD dataset (n=585), I found
significant positive correlations (p-value ≤ 0.001) for 5 genes (DDX3X, HSP7C,
CPSF5, IF2G, SF3A1) and significant negative correlations for 3 genes (PUF60,
EIF1A1, RSMB) (Table 2.1B and Figure 2.3A-2.3H). I then aimed to find whether
any correlation existed between these genes and CD274 mRNA. This analysis
revealed 2 genes with weak positive correlations (DDX3X, HSP7C) and four
genes with moderate negative correlations (PUF60, GRP78, RSMB, IF2G)
(Table 2.1C, and Figure 2.4A-2.4F).

2.4

Discussion

In this chapter, information obtained from publicly-available protein and
gene expression datasets was used to gain real-world insight into my
overarching research question: does SHP-2 activity or expression influence PDL1 mRNA and protein levels and subsequent response to anti-PD-1 or PD-L1
therapies in NSCLC? I used this approach because I believe that the utilization of
patient tumor datasets can inform and direct wet-lab experimentation. The design
and execution of pre-clinical and clinical studies is expensive, time-consuming,
and labor-intensive. Here, a simple and efficient process is presented that, when
combined with bench-side experimentation, can offer substantial insight into the
clinical translatability of commonly-used, highly-controlled model systems
designed for drug discovery applications. Through the analysis of two major
cancer data repositories and two smaller clinical studies, I was able to take
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further steps towards establishing a connection between the activity of SHP-2
and PD-L1 expression in human tumors without carrying out a study de novo.

Of the datasets chosen for this study, the most statistically-powerful and
revealing information arose from the composite analyses of the TCPA and GDC
data repositories. Using genomic and protein information from a large cohort of
NSCLC patients, my most important observation was the significant negative
correlation between the active, tyrosyl-phosphorylated form of SHP-2 and PD-L1
protein expression (Figure 2.1A). A limitation of these data was that the RPPA
data did not include expression levels of the unphosphorylated and inactive form
of SHP-2 which would have been a useful control as informed by my wet-lab
studies. The conformational changes induced by phosphorylation of SHP-2 could
alter protein-protein interactions and intracellular signaling cascades that impact
PD-L1 expression (124). Following from that concern, I observed no statistically
significant correlation between the levels of SHP-2 and PD-L1 mRNA in the
patients in the NCI-GDC dataset that were initially studied in the TCPA dataset,
again highlighting the potential importance of molecular interactions of SHP-2
dependent on its activated state. Interestingly, when I conducted the same
analysis on the entire cohort of LUAD patients in the NCI-GDC repository, a
weak, but inverse correlation between PTPN11 and CD274 mRNA was
observed, enforcing that the activity of SHP-2 is likely of greater importance in
PD-L1 regulation than mRNA expression. It is important to note that activity of
SHP-2 is not necessarily impacted by the level of expression.

When I embarked on these studies, I most desired to understand how SHP2 influences response to ICI therapy in KRAS-active tumors to direct my drug
discovery efforts in a wet lab setting. A limitation of the data deposited in the NCIGDC is that the clinical data are often incomplete and lacking details on drug
treatment and associated response or perhaps pre-date a particular therapy, like
ICIs in this case. However, I was able to address the expression of SHP-2 and
PD-L1 in KRAS active LUAD (~26% of the tumors). KRAS status did not change
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the outcome of the analysis. I identified other studies in which RNA-seq data was
collected from tumors treated with ICIs, one in melanoma and one in NSCLC
(122) (123). While the focus of this study is on NSCLC, treatment of melanoma
using ICIs was approved several years prior to use in NSCLC, and thus the data
available in this cancer with respect to ICI treatment is more mature. It should be
noted that melanomas rarely harbor KRAS mutations and more often HRAS
mutations. Additionally, Raf mutations are more likely the oncogenic drivers of
cell division in melanoma tumors. Neither of the two small studies made the
mutation status of Ras available.

The melanoma study was embarked by Regev and colleagues (122) to
identify a gene expression profile that is associated with immune evasion that
might predict response to ICI treatment. They conducted scRNA-seq on
melanoma tumors that were either treatment naïve at that time or had acquired
resistance to ICI therapy. These data allowed me to test whether PTPN11 and
CD274 gene expression associated with response to therapy. The authors of the
study were more interested with defining signatures of resistance that could be
used to screen patients prior ICI therapy, so the experimental design was not
ideal for my hypothesis and the sample size was small. As observed in the TCPA
and NCI-GDC analysis, melanoma tumors also demonstrate that higher PTPN11
expression was associated with less CD274 mRNA expression. Importantly,
PTPN11 mRNA levels were roughly equivalent between the treatment naïve and
ICI resistant tumors. While this analysis provides some insight into the landscape
of SHP-2 and PD-L1 co-expression, it is important to acknowledge that these
tumors are not lung tumors, have different oncogenic mutations, and study
sample sizes were relatively low.

Data from the NSCLC study carried out by Hwang and colleagues in which
they sought to identify immune gene signatures that may predict clinical
response to anti-PD-1 therapy were re-purposed for another question (123).
Expression of PTPN11 did not associate with DCB, but the tumors from patients
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who experienced DCB displayed increased expression of CD274 mRNA,
consistent with other studies (68)(125)(126) (Figure 2.3A-2.3B). Taken together,
SHP-2 activity, not expression, may be important for PD-L1 expression in
NSCLC and subsequent response to anti-PD-1 and -PD-L1 therapy.

Finally, using data from wet lab experimentation, bioinformatic techniques
were used to further investigate the mechanism by which SHP-2 regulates PD-L1
expression. RNA-seq data from the NCI-GDC were used to search for
correlations in mRNA expression of proteins that co-precipitate with SHP-2, as
identified by mass spectrometry. From that mass spectrometry screen for SHP-2
interactors, ten proteins were selected for exploration, eight are known to be
involved in mRNA processing, and two are involved in protein transport and
maintenance (Table 2.1A). The primary objective from this analysis was to inform
and direct subsequent wet-lab experimentation by determining if the proteinprotein interactions observed from in vitro cell culture could be corroborated by
the co-expression of the mRNA which encodes these proteins in NSCLC patient
tumors. As such, the findings presented in this chapter will be discussed later
and in greater detail in chapter 4.

From these analyses, the most striking observation was the strong
correlation between mRNA expression of the RNA helicase DDX3X and SHP-2 (r
= 0.4841, p-value < 0.0001) (Figure 2.4A). DDX3X was one of the highest
scoring proteins across multiple repetitions of the mass spectrometry screen, and
therefore, this finding supports the hypothesis that SHP-2 and DDX3X interact
within the context of a NSCLC tumor. Importantly, DDX3X contains a tyrosine
phosphorylation site at Y104, making it a potential substate for SHP-2. In addition
to DDX3X, four other proteins (Table 2.1B, Figure 2.4B-2.4E) had positive
correlations with SHP-2 mRNA expression, three of which (CPSF5, IF2G,
SF3A1) are mRNA processing proteins and one (HSP7C) a protein chaperone.
However, there exists no experimental evidence that any proteins other than
DDX3X are phosphorylated on tyrosine residues. This finding suggests that SHP46

2 may be involved in the processing and regulation of mRNA within LUAD
tumors, a novel function of SHP-2. However, as stated above, the activity of
SHP-2 may be of greater importance than its expression regarding PD-L1
expression, though unfortunately there does not exist protein expression data for
DDX3X on TCPA. Although there is a strong positive correlation in the mRNA
expression of SHP-2 and these five proteins, these data provide no information
on the activation status of SHP-2 or if it directly interacts with these proteins in
vivo.

The same analysis was then repeated, this time compared with the mRNA
expression of CD274. HSP7C, which positively correlated with CD274 mRNA, is
a molecular chaperone, and PD-L1 is expressed on the cell surface. Therefore, it
is reasonable to suggest that these two proteins would be co-expressed, if
indeed PD-L1 is a substrate for trafficking by HSP7C. Interestingly, DDX3X
mRNA also correlated with that of PD-L1, though the statistical confidence (pvalue = 0.0013) is relatively weak for this type of analysis (Table 2.1C, Figure
2.5A).

There are limitations to these analyses that warrant consideration. First,
these data only describe the expression of mRNA of pairs of genes and not of
protein. While it is well understood that when the mRNA of a gene is expressed,
often the protein is as well, however this is not always the case as there are
many mechanisms that influence the translation of mRNA into protein such as
miRNA involvement and mRNA degradation/metabolism (127)(128). Second,
RNA-seq data requires special considerations when evaluating the statistical
significance of the findings. When comparing the mRNA expression of 20,000
unique genes, the likelihood of false discoveries is much higher than in smaller
data sets, and so correlations that do not have very high confidence (p-values <
0.001) of statical significance should be observed with caution (129)(130).
Contrary to the retrospective analyses of massive genetic datasets collected
under conditions I was unable to control, the genes I chose to investigate were
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not random findings of a fishing expedition, but rather are supported by and
identified from controlled biochemical assays. It has been suggested that pure in
silico interrogations of differential gene expression may encompass considerable
pitfalls when applied to large datasets, such as those contained within the GDC.
Thus, the decision to reinforce my informatic interrogations with reproducible in
vitro experimental data further underpins the scientific rigor and reliability of
conclusions drawn from these analyses. Furthermore, the primary intent of these
exploratory analyses was to inform and direct further bench-top molecular
interrogation and not serve as the sole information upon which final conclusions
are to be drawn. Going forward, these hypotheses will be tested using in vitro cell
based assays altering SHP-2 activity and expression to help ratify the inferences
from this chapter.

2.5

Conclusions

The value of simple, but grounded, methods to use real-world data and apply the
information gained from this study to direct new wet lab experimentation should
not be overlooked. Each previously published study I used had limitations for my
purposes, but I operate within those limitations. Additionally, the strength and
versatility of these bioinformatics analyses are fortified when combined with
benchtop molecular analyses. Together they serve as powerful tools when
elucidating biological mechanisms. These data convince me that continued
exploration into the role of SHP-2 on both PD-L1 expression and response to
certain immune checkpoint inhibitors has value. Ultimately there is likely value in
combining the use of molecules that inhibit the activity of SHP-2, specifically in
lung tumors, and immune checkpoint inhibitors that depend on expression of PDL1 on tumor cell surfaces.
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Figure 2.1. SHP-2 activity and expression correlates with expression of
PD-L1 in NSCLC adenocarcinomas. A. Two-tailed non-parametric
Spearman correlation analysis of RPPA protein expression data for Y542
phosphorylated SHP-2 and PD-L1 from 362 adenocarcinomas taken from The
Cancer Proteome Atlas (TCPA: https://gdc.cancer.gov/aboutdata/publications/pancanatlas) LUAD-L4 dataset. B. Two-tailed nonparametric Spearman correlation analysis of bulk RNA-seq FPKM-UQ values
taken from TCGA (GDC) for the 362 patients that had corresponding RPPA
protein expression data from TCPA. C. Two-tailed non-parametric Spearman
correlation analysis of bulk RNA-seq FPKM-UQ values taken from TCGA
(GDC) for all 585 patients in the TCGA-LUAD dataset. D. Two-tailed nonparametric Spearman correlation analysis of mRNA z-scores taken from
cBioPortal (PMID:32015526) for 169 lung adenocarcinoma tumors. The red
line in each panel represents a linear regression line of best fit.
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Figure 2.2. Workflow scheme for evaluation of SHP2 and PD-L1
relationships. Reverse-phase protein array (RPPA) was collected from the
TCPA data repository (https://gdc.cancer.gov/aboutdata/publications/pancanatlas) for 362 total patients labeled as the TCPALUAD-L4 data set. RNAseq data was collected from GDC for the full TCGALUAD dataset (n=585). These data were parsed to include only patients for
which there was matching RPPA data on TCPA (n=362). Single-cell RNAseq
reads for 31 melanoma tumors were collected and separated into two groups
based on ICI treatment status. Only single-cell reads for ‘malignant melanoma
cells’ were retained for analysis. Tumors which had ≥ 30 unique malignant
cells with non-zero PTPN11 values were included in the analysis. NSCLC
tumors (n=21) with sequence data were first separated into two groups based
on response to ICI treatment. Average TPM values were calculated for
PTPN11 and CD274, and tumors that had PTPN11 TPM value >2 standard
deviations from the mean were excluded from the analysis.
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Figure 2.3. CD274, but not PTPN11, mRNA expression is associated
with response to ICI in NSCLC tumors. A. PTPN11 TPM values for
patients who did or did not demonstrate a durable clinical benefit (DCB) from
ICI therapy, as determined by RECIST criteria (123). There was no
significant difference between groups, as measured by a student’s t-test. B.
TPM values for CD274 in patients who did or did not demonstrate a durable
clinical benefit (DCB) from ICI therapy, as determined by RECIST criteria.
There was no significant difference between groups, as measured by a
student’s t-test.
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Figure 2.4. Genes identified in mass spec screening correlate with PTPN11
expression in NSCLC adenocarcinomas. Two-tailed non-parametric
Spearman correlation analysis of of bulk RNA-seq FPKM-UQ values taken from
TCGA (GDC) for all 585 patients in the TCGA-LUAD dataset for PTPN11 and A.
DDX3X B. HSP7C C. GPSF5 D. IF2G E. SF3A1 F. PUF60 G. EF1A1 H. RSMB.
The red line represents a non-linear regression line of best fit.
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Figure 2.5. Genes identified in mass spec screening correlate with CD274
expression in NSCLC adenocarcinomas. Two-tailed non-parametric
spearman correlation analysis of bulk RNA-seq FPKM-UQ values taken from
TCGA (GDC) for all 585 patients in the TCGA-LUAD dataset for CD274 and A.
DDX3X B. HSP7C C. PUF60 D. GRP78 E. RSMB F. IF2G. The red line
represents a non-linear regression line of best fit.
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Table 2.1. Proteins that co-precipitate with SHP-2 identified by mass
spectrometry correlate to PTPN11 and CD274 mRNA expression in
NSCLC adenocarcinomas. A. Table of the top 10 scoring proteins that coimmunoprecipitated with SHP-2 as identified by mass spectrometry that
includes their score value as well as their biological function. B. Table
depicting the values of a two-tailed non-parametric spearman correlation
analysis of bulk RNA-seq FPKM-UQ values taken from TCGA (GDC) for all
585 patients in the TCGA-LUAD dataset for proteins that co-precipitated with
SHP-2 analyzed against PTPN11 or C. CD274.

A
Protein

MS
score

HSP7C

540.88

DDX3X

511.12

PUF60

482.65

CPSF5

387.32

EIF1A1

353.86

GRP78

321.38

RSMB

244.19

KPYM

234.93

IF2G

184.97

Eukaryotic initiation factor (e-IF2) subunit

SF3A1

119.2

pre-mRNA splicing; SF3A complex

Function
Protein folding and transport, protein complex formation,
proteome stress protection
RNA-Helicase; binds rG4s structures, including in 5'-UTS of
NRAS
DNA/RNA binding protein; RNA splicing, apoptosis, and
transcription regulation
Cleavage factor complex; activator of pre-mRNA-3' end
cleavage. mRNA maturation.
Elongation initiation factor complex subunit. Th1 specific
TF, binds to IFNγ promoter
ER chaperone, protein folding, degrades misfolded
proteins
pre-mRNA splicing; SMN-Sm complex, component of
snRNPs
Pyruvate kinase, stimulates POU5F1-mediated
transcriptional activation. Assists in caspase cell death in
tumor cells
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B
Protein
DDX3X
HSP7C
CPSF5
IF2G
SF3A1
Protein
PUF60
EIF1A1
RSMB

C
PTPN11 + correlation
Correlation
p-value
0.4841

< 0.0001

0.1396

0.0006

0.3152

< 0.0001

0.1604

< 0.0001

0.3226

< 0.0001

Protein
DDX3X
HSP7C

0.0003

-0.1518

0.0002

-0.1929

< 0.0001

0.1316

0.0013

0.1149

0.0051

CD274 - correlation
Correlation
p-value
PUF60
GRP78
RSMB
IF2G

PTPN11 - correlation
Correlation
p-value
-0.1473

CD274 + correlation
Correlation
p-value
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-0.2527

< 0.0001

-0.2754

< 0.0001

-0.2269

< 0.0001

-0.1206

0.0032

Table 2.2. PTPN11 mRNA expression weakly associated with
reduced CD274 mRNA expression in melanoma tumors
regardless of ICI exposure. A. Six tumors had ≥ 30 unique malignant
cells that had non-zero PTPN11 and are ICI therapy naïve. Shown are
the percentage of single cells that expressed PTPN11, the combined
TPM values for all the single cells within each individual tumor, and the
average TPM values for all 6 untreated tumors combined. B. The
same details as (A) but for tumors that did not respond to ICI therapy.
There was no significant difference in average PTPN11 and CD274
TPM values between treatment naïve and treatment resistant groups.
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CHAPTER 3.

3.1

Overview
Non-small cell lung cancer (NSCLC) remains one of the most onerous forms

of cancer. In 2020, it was estimated that roughly one quarter of all cancer-related
deaths will be due to cancer of the lung and bronchus (22). The severity of the
disease can be attributed to late-stage diagnoses and the rapid resistance of
NSCLC to both cytotoxic chemotherapy and targeted therapies, resulting in a poor
5-year survival rate of 20% (131). In NSCLC, as many as one third of tumors harbor
mutations in RAS genes, especially KRAS, a protein which until recently has been
exceptionally difficult to target with small molecule inhibitors (132)(133)(134). The
RAS protein is a GTPase which, in response to growth factor stimulation, is
activated, providing a trigger for initiation of intersecting signaling cascades that
drive proliferation and cell survival.

Historically, direct inhibition of the KRAS protein or downstream effector
proteins (such as farnesyltransferases) with small molecules has proven
exceptionally difficult in providing control of tumor growth (135). Thus, treatments
for patients with tumors harboring KRAS mutations remain limited to cytotoxic
chemotherapies or immune checkpoint inhibitors (136). Monoclonal antibodies that
interfere with PD-1/PD-L1 checkpoints between tumors and cytotoxic/effector Tcells have shown substantial clinical benefit for a subset of patients without EGFR,
ALK, or ROS actionable mutations (137). Importantly, evidence is mounting that
suggests that many KRAS-active tumors possess the unique characteristic of
aberrant expression of PD-L1. In a 2018 study examining 219 lung
adenocarcinomas (83), Falk et al. (2018) observed that KRAS-active tumors
maintained significantly higher PD-L1 expression than KRAS-wildtype tumors, and
that increased PD-L1 expression was associated with improved overall survival
(138). In a meta-analysis of over 23 studies, Liu et al. (2020) observed that KRASactive NSCLC is more likely to be PD-L1 positive compared with wild-type tumors
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(137). Furthermore, they observed that patients harboring KRAS-active tumors
displayed a significantly higher overall response rate to PD-L1 blockade. Together,
these studies suggest that KRAS-active NSCLC may be particularly susceptible to
interruption of the PD-L1/PD-1 interaction.

The ability of the immune system to identify and target tumors is a natural
process that occurs irrespective of pharmacological intervention. In the 1960s and
1970s, immune cells were further classified as cytotoxic T-cells and dendritic cells
with specific functions, for example, and in 1975 natural killer cells were found to
specifically target leukemia cells in mice (139)(140)(141). Within the past several
decades, proteins involved in modulating the immunological identification and
targeting of tumors have received a great deal of scientific attention. One such
protein, PD-L1, has been shown to play a crucial role in modulating immune
response and T-cell activity. PD-L1 is normally expressed on the surface of cells
of the immune system, usually antigen presenting cells, as a mechanism by which
the immune system distinguishes self from non-self (142). Specifically, ligation of
PD-L1 to the receptor PD-1, which is found on the surface of activated T-cells,
results in T cell deactivation and protection of self. When PD-L1 is expressed on
tumor cells and engages PD-1 on effector T cells the tumor is hidden from cytotoxic
T cells. Once the PD-1/PD-L1 interaction is interrupted, the tumor can now be
targeted by the immune response. After Honjo et al. (1992) uncovered the biology
of this interaction, antibodies that bind either PD-1 and PD-L1 were developed to
unmask the tumor from the immune system and have shown substantial clinical
benefit for many solid tumors (142)(143)(144).

Although several studies have demonstrated that KRAS-active cancers often
have increased levels of PD-L1 expression, the precise mechanism(s) by which
PD-L1 is aberrantly expressed in KRAS-active cancers remains unclear. It is likely
that multiple signaling pathways, such as PI3K/AKT/mTOR and EGFR, govern PDL1 expression (145)(146)(147)(148)(149). One mechanism reported by Coelho et
al. (2017) showed that oncogenic RAS signaling leads to dysregulation of the RNA61

binding protein, TTP, that can upregulate PD-L1 expression by stabilizing PD-L1
mRNA (83). Other studies demonstrate that cytokine-activated pathways, such as
JAK/STAT, also impact the normal expression of PD-L1 in immune cells (and also
may be the case in some cancer subpopulations), specifically through interferon
gamma-induced activation of the transcription factor, signal transducer and
activator

of

transcription-3

(STAT3)

(150)(151)(152).

Additionally,

post-

translational modifications to PD-L1 protein can influence its metabolism and
localization within a cell. Glycosylation of PD-L1 has been shown to impact PD-L1
stability, thus influencing its ability to impede T-cell activation in cancer cells (153).
Phosphorylation of PD-L1 on Ser/Thr residues by GSK3β alters the interactions of
PD-L1 with E3 ligases and thus the extent of PD-L1 ubiquitination, further
influencing protein turnover and activity (154).

In prior work from this laboratory, mRNA and microRNA gene expression
profiles that differentiated mRNA expression levels in KRAS-active and EGFRmutant lung cancer cell lines were mined using novel bioinformatic approaches to
examine co-incident changes in mRNA and microRNA expression to identify
potential therapeutic targets for KRAS-active NSCLC (155). One of the potential
targets identified that warranted further exploration was the non-receptor tyrosine
phosphatase, Src homology region 2 containing protein phosphatase (SHP-2).
SHP-2 has been implicated in regulating the RAS/Raf/ERK pathway as well as
integrating the activities of the JAK/STAT and PI3K/Akt/mTOR survival pathways
(124)(156)(157). Along with other laboratories, we initially hypothesized that SHP2 might be a direct therapeutic target for KRAS-active NSCLC in the absence of
efficacious KRAS inhibitors (106)(107)(158). The preponderance of evidence from
our lab and others indicates that inhibition of SHP-2 is unlikely to cause cell death
and forced us to consider other explanations for our observations.

SHP-2 is encoded by the PTPN11 gene and contains two SH-2 domains that
are used to dock phosphorylated tyrosine residues of substrate proteins, and a
catalytic protein tyrosine phosphatase (PTP) domain that can act upon those
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substrates. Following receptor tyrosine kinase (RTK) activation, SHP-2 is recruited
to the cell membrane and may be phosphorylated at two Tyr residues (Y542 and
Y580) on the C-terminal domain, though the kinases responsible for such
phosphorylation events remain understudied. Once in an active conformation,
SHP-2 may interact with other proteins involved in RAS signal transduction such
as Grb2 and SOS, resulting in subsequent ERK activation, tumor proliferation,
growth, and survival (159)(160). It is thought that both the ability of SHP-2 to
enucleate this protein complex, as well as catalytic phosphatase activity both play
a role in these signal transduction events (108). SHP-2 loses phosphatase activity
when the N-SH2 domain folds on the phosphatase domain leading to autoinhibition (161). However, activating mutations can occur in the N-SH2 or PTP
domains of the PTPN11 gene and lead to a protein that has disrupted autoinhibitory activity associated with unfolding of the protein resulting in a
constitutively-active phosphatase. The phosphatase domain of SHP-2 is
responsible for dephosphorylation and deactivation of p120-RASGAP, a negative
regulator of ERK activation, as well as a collection of other proteins (159)(160).
Though the catalytic phosphatase activity of SHP-2 contributes to its signal
transduction capabilities, it is also capable of serving as a scaffold that enucleates
protein complexes, specifically through interactions of its SH2 domains with p-Tyr
residues on protein substrates (162). Dissecting the relative influence of SHP-2
PTP activity from scaffolding functionality is of critical importance as it relates to
PD-L1 expression.

My initial experiments aligned with the published work of others that
pharmacological inhibition of SHP-2 activity does not lead to cell death of NSCLC
cell lines (106). However, I found that ablation of SHP-2, and to a lesser extent
inhibition of phosphatase activity, did alter the expression of PD-L1. I postulated
that SHP-2 engages in a multi-protein complex to control PD-L1 mRNA expression
in KRAS-active cells that does not require phosphatase activity. The future
implications of this work are that inhibition of SHP-2 may synergize with ICI therapy
in NSCLC by promoting the expression of PD-L1.
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3.2

Methods

Cell lines and treatment conditions

KRAS-active NSCLC cell lines NCI-H460 and A549 were acquired from
ATCC (STR authenticated) and UKY-29 cells were developed by, and a gift from,
John Yannelli, Ph.D. at the University of Kentucky, College of Medicine (163). Cells
were seeded at 1x105 cells/well on a 6-well plate for flow cytometry, or 2x104 on a
24-well plate for qRT-PCR and western analysis. Cells were allowed to adhere and
grow for 24 hours in RPMI 1640 containing 10% fetal bovine serum (FBS), 100
U/mL penicillin, 100 µg/mL streptomycin and maintained at 37°C, 5% CO2. For
assays involving treatment with SHP099, RMC-4550, SHP-2 siRNA or CRISPR,
media was then removed and replaced with RPMI 1640 containing 1% FBS for 24
hours. Media was again replaced with RPMI 1640 containing 1% FBS with either
a final concentration of [10μM] of the SHP-2 inhibitor SHP099 (Novartis), [20nM]
of RMC-4550 (SelleckChem), or vehicle (4% DMSO). For genetic ablation of SHP2, media was removed and replaced with RPMI 1640 containing 1% FBS and no
antibiotics.

Cells

were

then

transfected

with

Lipofectamine

RNAiMAX

(ThermoFisher) and SHP-2 siRNA [30nM] (Cell Signaling Technologies) or
SignalSilence Control siRNA (Cell Signaling Technologies, #6568). A Cas9-guide
RNA complex (New England Biolabs) or a non-targeting CRISPR/Cas9 guide RNA
was transfected using Lipofectamine RNAiMAX. Following all treatments, cells
were incubated for another 24 hours prior to harvest for western analysis in 100µl
protein sample buffer (62.5mM Tris-HCL pH 6.8, 2% SDS, 10% Glycerol, 5% βmercaptoethanol, bromophenol blue) or for qRT-PCR in 350µl buffer RLT
(QIAgen). Cells plated on 6-well plates designated for flow cytometry were washed
with ice cold Ca+/Mg+ free PBS prior to trypsinization and flow cytometric analysis.

CRISPR/Cas9 SHP-2 knockout

Guide RNA (gRNA) targeting exon 3 of PTPN11 (SHP-2) was generated
using the CHOPCHOP online web tool (https://chopchop.cbu.uib.no/), resulting in
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a gRNA sequence of GATTACTATGACCTGTATGG. The DNA oligonucleotide
was synthesized by IDT technologies and used to generate gRNA with the EnGen
sgRNA Synthesis Kit (New England BioLabs). Cells were seeded at 1x105
cells/well on a 6-well plate or 2x104 cells/well on a 24-well plate for 24 hours in
RPMI 1640 containing 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and
maintained at 37°C in 5% CO2. Media was then replaced with RPMI 1640
containing 1% FBS for another 24 hours. Media was removed and replaced with
RPMI 1640 containing 1% FBS and no antibiotics prior to CRISPR treatment.
gRNA was complexed with EnGen Spy Cas9 NLS (New England BioLabs) and
added to wells for 48 hours for western analysis or 24 hours for flow cytometry.
Cells were then lysed in 100μl protein lysis buffer for western blotting or 350μl
buffer RLT for RNA extraction and RT-qPCR.

Flow Cytometry

Following treatment, cells were washed with cold Ca2+/Mg2+-free PBS
(VWR) and detached using trypsin-EDTA 0.05% (ThermoFisher). After a 5-minute
centrifugation at 300xg and 4°C, supernatant was removed and cells were
resuspended in cold FACS buffer (pH 7.0: 1X PBS, 1mM EDTA, 25 mM HEPES,
1% heat-inactivated FBS) and transferred to a 96-well round bottom plate (Nunc)
at 2x105 cells/well for staining. Cells were stained with fluorescent-conjugated
antibodies specific for PD-L1 (PE) and EGFR (Alexa Fluor 647) (BD Biosciences)
and fluorescence was measured using (Sony SY3200). UltraComp eBeads
(Thermo Fisher) were used for fluorescence compensation. Analysis was
performed using FlowJo v. 10 (Tree Star) and incorporated live and singlet gates
prior to gating on individual markers. Flow cytometry was performed by the
University of Kentucky flow cytometry core facility.
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Western blot analysis

Following treatment and harvest, cells were lysed with protein sample
buffer, subjected to a freeze/thaw cycle, sonicated, then heated to 95°C for 5
minutes prior to protein separation using 10% SDS-polyacrylamide gel
electrophoresis (PAGE) at 135V for 80 minutes. Proteins were transferred to a
nitrocellulose membrane and blocked in Tris-buffered saline (TBS) containing
0.1% Tween 20 and 5% bovine serum albumin for 30 minutes prior to overnight
incubation at 4°C with primary antibody: SHP-2 (#3397), PD-L1 (#13684), or
GAPDH (#2118) (Cell Signaling Technologies). After overnight incubation,
antibody was removed, and blots were washed with TBS containing 0.1% Tween
20. Secondary HRP-labeled antibodies were applied to the blot in 5% non-fat, dry
milk in 1X TBS containing 0.1% Tween 20 for one hour. The blot was washed three
times for 5 minutes each in 1X TBS containing 0.1% Tween prior to developing
and detection of HRP signal. Signal was quantified using ImageJ software (NIH)
and values for SHP-2 and PD-L1 were normalized to GAPDH.

Quantitative real-time PCR (qRT-PCR) analysis

Total RNA was extracted from lysed cells using the RNeasy kit (Qiagen).
cDNA was then generated using the iScript cDNA synthesis kit (BioRad). qRTPCR was performed using human TaqMan primer probe sets (Thermo- Fisher)
for PD-L1 (Assay ID: Hs00204257_m1), SHP-2 (Hs06636344_g1), GAPDH
(Hs02786624_g1) and β-Actin (Hs99999903_m1). qRT-PCR data were analyzed
by calculating ΔCt values for PD-L1 by standardizing PD-L1 Ct values against
those for the averaged Ct values of housekeeping genes GAPDH and β-Actin.
PD-L1 ΔCt = (PD-L1 Ct) – (GAPDH Ct + β-Actin Ct / 2)
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Statistical analysis

For flow cytometry, the raw cell counts for cells expressing PD-L1 for three
separate experiments were averaged and a student’s t-test was applied to
determine statistical significance. For qPCR analysis, ΔCt values for three
separate experiments were then averaged and a student’s t-test was applied to
determine significance.

3.3

Results

PD-L1 mRNA abundance is increased in SHP-2 ablated cells

To determine whether pharmacological inhibition or genetic ablation of
SHP-2 altered expression of PD-L1 mRNA, total RNA was prepared from A549,
H460, and UKY-29 cells that were treated with SHP-099, RMC-4550, SHP-2
siRNA, or CRISPR. qRT-PCR was used to quantify levels of PD-L1 and GAPDH
mRNA following treatments. The abundance of PD-L1 mRNA was not significantly
changed in any cell line with SHP-2 pharmacological inhibitors or siRNA treatment
(Figure 3.1). Specifically, in H460 and A549 cells, treatment with siRNA or RMC4550 caused slight, but not statistically significant, increases in PD-L1 mRNA as
indicated by a reduction in dCt values. CRISPR/Cas9-mediated knockout of SHP2 resulted in significant increases in PD-L1 mRNA in all three cell lines (Figure
3.1). I used CRISPR/Cas9-mediated ablation to confirm that the findings from
siRNA-mediated ablation. CRISPR/Cas9 ablation is more reliable, but transfection
of the gRNA complexes tends to be more toxic to these cells.

PD-L1 protein expression is increased in SHP-2 ablated cells

Following from the mRNA analysis, I then asked whether PD-L1 protein
levels changed consistently with the changes in mRNA expression. Western blot
analysis revealed that PD-L1 protein expression increased in all three cells treated
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with CRISPR (Figure 3.2A-3.2F). Specifically, in CRISPR-treated H460 cells, an
83% reduction in SHP-2 resulted in a five-fold increase in PD-L1 relative to control
(Figure 3.2A, 3.2B); in A549 cells, a 92% reduction of SHP-2 resulted in a greater
than ten-fold increase in PD-L1 relative to control (Figure 3.2C, 3.2D); and in UKY29 cells, a 78% reduction of SHP-2 resulted in an eight-fold increase (Figure 3.2E,
3.2F) relative to control. Although siRNA ablation is not as efficient as CRISPR in
all cells, H460 cells treated with siRNA also showed an increase in PD-L1
expression consistent with CRISPR ablation. In both UKY-29 and H460 cells,
treatment with allosteric SHP-2 inhibitor RMC-4550 led to 1.5-fold and 3.5-fold
increases in PD-L1 expression, respectively, relative to untreated cells. SHP099
treatment did not lead to increased PD-L1 expression over that of the vehicle
controls. Additionally, the negative control cell transfections with either
SignalSilence Control siRNA or non-targeting CRISPR/Cas9 guide RNA are
shown in Figure 3.5.

Expression of PD-L1 on the cell membrane increased after SHP-2 ablation

Because cell surface expression of PD-L1 is required for therapeutic antibody
binding and is often measured prior to initiation of ICI therapy for frontline ICI
therapy decisions, I investigated whether cell surface expression of PD-L1 also
changed in response to pharmacological inhibition or genetic ablation of SHP-2.
Following the same conditions used to assess mRNA and protein levels, I
measured cell surface expression of PD-L1 and EGFR as a control using flow
cytometry. An increase in PD-L1 cell surface expression was observed in A549
(Figure 3.3, 3.4B), H460 (Figure 3.4A), and UKY29 (Figure 3.4C) cell lines
following treatment in CRISPR/Cas9-mediated SHP-2 knockouts and consistent
with, but to a lesser extent than, siRNA treatment. Specifically, H460 cells
demonstrated a 33.7% increase in PD-L1 surface expression; A549 cells showed
62.9% increase in PD-L1; and UKY-29 cells demonstrated a 27% increase in PDL1 surface expression following CRISPR knockout of SHP-2 (Figure 3.4B-3.4D).
EGFR surface expression was measured as a control surface protein and was
68

unaltered by any treatments. These results follow from total protein analyses that
loss of SHP-2 increases both total and PD-L1 expressed on the cell membrane.

3.4

Discussion
In this chapter, I present my efforts to understand the impact of the tyrosine

phosphatase SHP-2 on the tumor expression of PD-L1. Currently, tumoral
expression of PD-L1 is a guideline measure to initiate anti-PD-1 and PD-L1
therapies in some lung cancer settings. Specifically, for newly diagnosed NSCLC
patients, treatment with a PD-1 antibody (pembrolizumab) is dependent on tumoral
expression of PD-L1 that must be greater than 50% to initiate therapy and for
second-line therapy, greater than 1% (164). Importantly, PD-L1 expression levels
in tumor biopsies are impacted by many variables: heterogeneity of cell types
within the tumor, region of the tumor tested, and the individual antibody/platform
combination utilized which is often unique for an individual therapeutic entity (164).
It is also reasonable to expect that control of PD-L1 expression differs within and
among tumors. Given the clinical implications of the variability of PD-L1
expression, a comprehensive understanding of the regulatory mechanisms
controlling when and where PD-L1 is expressed on tumor cells is vital.

Prior studies found that PD-L1 expression is aberrantly upregulated in KRASactive NSCLC. Importantly, Coehlo et al. (2017) implicated the kinase and
phosphatase pair of ERK and PP2A in control of the RNA-binding protein, TTP,
that preserves PD-L1 mRNA stability (83). I found that the absence of SHP-2
activity via pharmacological inhibition of phosphatase activity contributed to
increased PD-L1 expression in some KRAS active cells. I hypothesized that SHP2 exerts control over PD-L1 expression downstream of growth factor
signaling/KRAS signaling by impacting transcription initiation. Dissection of this
process is of primary importance wherein pharmacological inhibition of SHP-2 may
have therapeutic value in combination with PD-L1/PD-1 antibodies (145)(165).
Notably, the proposed mechanisms of PD-L1 regulation in cancerous cells are
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unlikely to mirror the normal regulation of PD-L1 expression in healthy cells.
Therein lies the possibility that in malignant cells, PD-L1 regulatory mechanisms
may be altered by the accumulation of multiple mutations that impact aberrant PDL1 expression.

While my initial observation that loss of SHP-2 function resulted in increased
PD-L1 levels, the level of expression of PD-L1 differs among cell lines. As other
laboratories have observed, PD-L1 expression is highest in KRAS active cells
(83)(137). Treatment with small molecule inhibitors of SHP-2 had minimal impact
on PD-L1 mRNA levels, suggesting that the phosphatase activity associated with
SHP-2 is not important at this level of control (Figure 3.1). Importantly, ablation of
SHP-2 with siRNA or CRISPR resulted in consistent increases in PD-L1 mRNA,
unlike treatment with small molecule inhibitors, also in Figure 3.1. These findings
hinted toward another role of SHP-2 in control of PD-L1 expression as it may
participate in a regulatory protein complex that controls PD-L1 mRNA or protein
half-life much like ERK/PP2A control of TTP (83)(166). Thus, allosteric inhibition
of SHP-2, with either SHP-099 or RMC-4550, may not interfere with the ability of
SHP-2 to interact with other proteins. Bivona (2019) suggests that a
GRB/SOS/GAB/SHP-2 complex transmits information from receptor tyrosine
kinases to the nucleus to regulate expression of a panel of genes necessary for
proliferation (167). It is unclear whether these interactions exclusively control the
flow of phosphates as secondary signals among proteins or other complex
interactions of proteins provide the control of expression of PD-L1. Finally, flow
cytometry analysis revealed that cell surface expression of PD-L1 increased in
cells with SHP-2 ablation consistent with the findings of Liu et al. (2017) (168). It
is however unclear whether these changes in surface expression are the result of
increases in total protein, or if there is some mechanism by which SHP-2 is
involved in trafficking PD-L1 to the cell surface. Further experimentation, such as
****come back to this****
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3.5

Conclusions
My results provide novel insight into additional regulatory mechanisms

governing the aberrant expression of PD-L1 in KRAS-mutant NSCLC. Ablation of
SHP-2 significantly increased PD-L1 mRNA and surface expression, while
pharmacological inhibition of phosphatase activity resulted in minimal changes in
PD-L1 levels. Furthermore, I hypothesized that the formation of multi-protein
complexes is controlled by SHP-2 and provide another layer of regulatory control
of PD-L1 expression. These observations hold both clinical and basic biological
implications. Ablation of SHP-2 may synergize with PD-L1 blockade in some
KRAS-active NSCLC and should be predicted by the expression levels of PD-L1.
Thus, dissection of the unreported activities of SHP-2 protein complexes in the
regulation of mRNA processing and trafficking of PD-L1 may offer additional
insights for both biomarkers and therapy.
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Figure 3.1. PD-L1 mRNA expression depends on SHP-2. PD-L1
mRNA levels were measured by qRT-PCR in H460, A549, and UKY29
cell lines treated with SHP099 [10μM], RMC-4550 [20nM], SHP-2
siRNA [30nM] or CRISPR/Cas9 mediated SHP-2 knockout. PD-L1 dCt
values for three independent experiments were generated using
GAPDH as a reference gene and then averaged. Error bars represent
standard deviation. Significance was determined using the students ttest (P<0.05).
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Figure 3.2. PD-L1 protein levels increase in the absence of SHP-2.
Representative western blots of A. H460 cell lysates, C. A549 cell
lysates, and E. UKY-29 cell lysates that were untreated or treated with
vehicle [4% DMSO], allosteric inhibitors SHP099 [10μM], RMC-4550
[20nM], and SHP-2 siRNA [30nM] or CRISPR/Cas9-mediated SHP-2
knockout. Densiometric quantification of SHP-2 and PD-L1 signal
normalized to GAPDH signal from B. H460 cell lysates (A), D. A549 cell
lysates (C), and F. UKY-29 cell lysates (E).
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Figure 3.3. PD-L1 surface expression increases in the absence of
SHP-2 in A549 cells. Representative pseudo-colored density plots of A549
cells treated with vehicle [4% DMSO], SHP099 [10μM], RMC-4550 [20nM],
SHP-2 siRNA [30nM] or CRISPR/Cas9-mediated SHP-2 knockout. The Yaxis represents EGFR-AlexaFluor 647 signal (control) and the X-axis
represents PD-L1-PE signal.
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Figure 3.4. PD-L1 surface expression increases in the absence
of SHP-2. Flow cytometry quantification of PD-L1 on the surface of
A. H460 cells, B. A549 cells, and C. UKY-29 cells expressing PD-L1
on their surface treated as described in figure 3.3. Three
independent experiments were averaged, and error bars represent
the standard error of the mean. Significance was determined using
the students t-test (P<0.05).
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Figure 3.5. Negative control siRNA and CRISPR gRNA do not
reduce SHP-2 expression. Representative western blots of H460,
A549, and UKY-29 cell lysates that were untreated (Un) or treated with
SignalSilence negative control siRNA [30nM] (si-NC) or CRISPR/Cas9
negative control gRNA (CR-NC). Bands for each cell line were all run
on the same gel and negative control bands were grouped next to
untreated cells for clarity.
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CHAPTER 4.

4.1

Overview
Over the past decade there has been growing interest in understanding the

multifaceted roles of tyrosine phosphatases as they relate to human cancers. It
has long been established that phosphorylation of tyrosine residues by tyrosine
kinases plays a critical role in the transmission of cellular signaling cascades that
regulate cell growth and survival (169)(170). Considering the gravity of tyrosine
phosphorylation events, it is logical to expect that the expression and activity of
negative regulators of these pivotal pathways should hold equal importance to
abnormal utilization by malignant cells (171). It is also important to note that the
relationship between kinases and phosphatases is more complex than the simply
positive or negative regulation of pathway activity; both classes of enzymes are
capable of more than functioning solely as “on/off” switches, and the addition or
subtraction of a phosphate group does not necessarily correspond to greater or
lesser activity. To begin dissecting the complex involvement of protein tyrosine
phosphatases in cell signaling pathways, this chapter aims to further elucidate the
mechanism by which the non-receptor tyrosine phosphatase SHP-2 is involved in
regulating the expression of genes downstream of RTK signaling, specifically PDL1.

SHP-2 has been shown to participate in the transmission of extracellular
signaling events mediated by several different RTKs and functions as a focal point
of intersecting signaling cascades such as the Ras/Raf/MEK, JAK/STAT, and
PI3K/mTOR pathways in cancer cells (124). In NSCLC, SHP-2 plays a critical role
in regulating oncogenic Ras signaling by forming a multi-protein complex with SOS
and Gab1/Grb2 at cytosolic phosphorylated tyrosine residues located on RTKs and
is required for the growth of KRAS-driven NSCLC (106)(107). Additionally, SHP-2
has been demonstrated to interact with the intracellular immunoreceptor tyrosinebased switch motif (ITSM) domain of the PD-1 receptor on activated T-cells and

macrophages. Upon ligation of PD-1 with its ligand, SHP-2 serves as a scaffold to
create a PD-1:PD-1 dimer which results in the activation of SHP-2, the
internalization the PD-1 receptor, and subsequent T-cell activation (172)(173).
Importantly, the mechanism of SHP-2-mediated activation and PD-1 internalization
has been shown to occur irrespectively of the catalytic phosphatase activity of
SHP-2, suggesting that SHP-2 may engage in signal transduction activities solely
through its ability to initiate protein complex formation (172)(174).

SHP-2 contains three major functional domains; two SH-2 domains (N-SH2,
C-SH2) that allow SHP-2 to associate with phosphorylated tyrosine residues
present on its protein substrates, and a catalytic phosphatase domain (175). On
the C-terminal domain (CTD) of SHP-2 reside two tyrosine residues (Y542 and
Y580) which may become phosphorylated, releasing SHP-2 from its autoinhibitory
conformation and allowing for catalytic PTP activity. Although it is well understood
that SHP-2 phosphorylation correlates with its activity, the exact tyrosine kinases
responsible for SHP-2 activation remain unknown.

Mutations in the PTPN11 gene which encodes SHP-2 have been linked to
several types of human diseases, including cancer (176)(177)(178)(179).
Noonan’s syndrome (NS) and Noonan syndrome with multiple letigines (NSML),
formerly known as LEOPARD syndrome, are diseases in which the regulatory
mechanisms for SHP-2 activation are altered (180). Activating mutations of SHP2, such as E76K, are associated with NS and juvenile myeloid leukemia, and the
E76K mutation is the most commonly found SHP-2 mutation in NSCLC tumors,
although the incidence of SHP-2 mutations is low in NSCLC (181). Such activating
mutations activate SHP-2 by disrupting the auto-inhibitory interactions between the
N-SH2 and PTP domains, resulting in constitutively active phosphatase activity.
Additionally, these mutations may impact the protein complex formation capability
of SHP-2, as demonstrated by Fragale et al. Specifically, SHP-2 mutants with
disrupted autoinhibitory activity maintained prolonged binding with adaptor
proteins Gab1/Grb2 (182).
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As previously described, the involvement of SHP-2 (whether through PTP
or scaffolding activity) in numerous immunomodulatory pathways suggests that
SHP-2 activity or expression would be capable of influencing PD-L1 levels. The
factors governing how and when PD-L1 is aberrantly expressed by malignant cells
are only beginning to be understood. However, there are multiple regulatory levels
of PD-L1 expression that have been described. For example, the activity of signal
transduction pathways such as the RAS/Raf/ERK, Jak/STAT, and PI3K/Akt/mTOR
all have been shown to influence transcriptional activity of PD-L1 (183)(184). More
specifically, NSCLC patient tumors harboring mutations in the KRAS gene have
upregulated levels of PD-L1, as well as improved responses to ICI therapy
compared to patients with wildtype KRAS. Coelho et al. demonstrated that
oncogenic RAS signaling can upregulate PD-L1 expression by stabilizing PD-L1
mRNA through the mRNA binding protein tristetraprolin (TTP) (83). Finally, post
translational modifications to PD-L1 such as glycosylation, ubiquitination, and
Ser/Thr phosphorylation have been shown to impact PD-L1 protein turnover and
metabolism, as well as the trafficking of PD-L1 to the cell surface (86)(185).

As described earlier in chapters 2 and 3, I observed that PD-L1 protein
significantly and negatively correlates with levels of active (p-Y452) SHP-2 in
NSCLC patient tumors, and that there also exists a slight positive correlation
between PTPN11 and CD274 mRNA levels. From my in vitro experimentation in
chapter 3, I observed increases in PD-L1 mRNA, protein, and surface expression
following genetic ablation of SHP-2 protein, concurrent with my finding that SHP-2
activity negatively correlates with PD-L1 expression in human tumors. Importantly,
I observed that inhibition of SHP-2 phosphatase activity with two small molecule
allosteric inhibitors of SHP-2 did not impact levels of PD-L1 expression, and thus
the ability of SHP-2 to enucleate protein-protein complexes may be of greater
importance than its catalytic PTP activity with regard to PD-L1 expression. To
begin unraveling the mechanism by which SHP-2 influences PD-L1 expression, I
first sought to pinpoint the layer of expression at which SHP-2 exerts control, as
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well as identify any protein binding partners of SHP-2 that may be responsible for
the PD-L1 phenotypes observed in earlier chapters.

4.2

Methods

Cell lines and treatments

For cycloheximide and actinomycin D treatments, NCI-H460 cells were
seeded at 2x104 cells/well on a 24-well plate in RPMI 1640 containing 10% FBS
and incubated at 37°C, 5% CO2 for 24 hours. Media was then removed and
replaced with RPMI 1640 containing 10% FBS and no antibiotics prior to
transfection with SHP-2 siRNA [30nM] (ThermoFisher) and Lipofectamine
RNAiMAX (ThermoFisher). After a 48-hour incubation with the lipid complexes,
media was removed and replaced with RPMI 1640 containing 10% FBS and either
Cycloheximide [10mg/mL] or Actinomycin D [1mg/mL]. Cells were harvested after
0, 2, 4, 6, 8, and 10 hours of exposure to either compound in protein sample buffer
for western blot analysis or buffer RLT (QIAgen) for RNA extraction and RT-qPCR.
To assess the status of SHP-2 expression in our cell lines of interest NCI-H460,
A549, and UKY29 cells were seeded at 2x104 cells/well in a 24-well plate in 1mL
of RPMI 1640 containing 10% FBS and incubated at 37°C, 5% CO2 for 24 hours.
Designated wells then had media removed and replaced with RPMI 1640
containing 1% FBS. After 24 hours, designated wells had FBS added back to a
final concentration of 10% and were allowed to incubate for another 24 hours prior
to harvest.

For growth factor stimulation assays, NCI-H460, A549, and UKY29 were
seeded at 2x105 cells/well in all well of a 6-well plate in 3mL of RPMI 1640
containing 10% FBS and incubated at 37°C, 5% CO2 for 24 hours. For five of the
wells, media was then replaced with 3mL RPMI 1640 containing 0.1% FBS. After
24 hours, FBS was added back to four of the starved wells and cells were

80

harvested 1, 2, 4, and 8 hours post addition of FBS. The remaining two wells were
harvested 48 hours after being plated.

For carfilzomib treatments, NCI-H460, A549, and UKY29 cells were seeded
at 2x104 cells/well on a 24-well plate in 1mL RPMI 1640 containing 10% FBS and
incubated at 37°C, 5% CO2 for 24 hours. Cells then were allowed to either remain
in 10% FBS RPMI 1640 for an additional 48 hours, or media was replaced with
1mL of 1% FBS RPMI 1640 and allowed to incubate another 24 hours. Finally,
designated cells had media removed and replaced with 10% FBS RPMI 1640 for
24 hours. Carfilzomib (SelleckChem) and/or FBS to a final concentration of 10%
FBS were added 72 hours after initial seeding to designated wells to a final
concentration of [50nM] for 8 hours prior to harvest. Cells were harvested in 100µL
protein sample buffer prior to protein separation by SDS-page and western blot
analysis.

For immunoprecipitations, NCI-H460 cells were seeded on a 60mm plate at
a density of 1x105 cells in 5mL of RPMI 1640 containing 10% fetal bovine serum
(FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and maintained at 37°C, 5%
CO2 for 24 hours. Media was then replaced with 2.5mL of RPMI 1640 containing
1% FBS and no antibiotics. Cells were transfected with 5mg of a plasmid construct
encoding wild-type (WT) SHP-2 fused to EGFP (AddGene, plasmid #12283) using
the Lipofectamine 3000 (ThermoFisher) transfection reagent and incubated for 48
hours to ensure the expression of SHP-2. Media was then removed, and cells were
washed with 5mL of ice-cold 1X phosphate buffered saline before lysing the cells
with 1mL ice-cold IP lysis buffer (50mM HEPES pH 7.5, 150mM NaCl, 1% Triton
X-100, 10% glycerol, 1.5mM MgCl2, 1mM EDTA) on ice for 5 minutes.

SHP-2 transfection and co-immunoprecipitation
Wildtype (WT)-SHP-2 transfected H460 cells were lysed then transferred into
a 1.5mL tube, sonicated three times with a handheld sonicator to disrupt cell
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membranes, and centrifuged for 10 minutes (>13,000xg) at 4°C. Half of the
supernatant was transferred to a new 1.5mL tube and a monoclonal SHP-2
antibody (Cell Signaling Technologies, #3397) was added at a dilution of 1:150
then rotated overnight at 4°C. The remaining supernatant was handled in the same
manner but without the addition of antibody.

The following day, protein A magnetic beads (10µL slurry per 100µL lysate;
Cell Signaling Technologies) were pre-washed 3 times with 5 times their volume
of IP lysis buffer and captured using a magnetic tube rack before being added to
the cell lysate. The slurry was incubated while rotating for 20 minutes at 4°C.
Protein-complexed magnetic beads were then collected in a magnetic tube rack,
washed 5 times with 5 times their volume of IP lysis buffer, washed three times
with 50mM HEPES pH 7.5, then captured and resuspended in 30µL protein sample
buffer. The samples were heated to 95°C for 5 minutes. Beads were collected and
the supernatant was loaded onto a 10% SDS-PAGE acrylamide gel and separated
at 135V for 70 minutes. The gel was then transferred to a clean glass container
containing Coomassie blue staining solution (2.5% Coomassie Blue, 10% glacial
acetic acid, 50% MeOH, 50% dH2O) and incubated, while rocking, at room
temperature for 60 minutes. Coomassie was then removed, and the gel was
washed twice with dH2O for 30 minutes before a final overnight de-staining in
dH2O. The gel was then transferred to a bio-safety cabinet and protein bands were
excised using a clean razor blade and then transferred to 1.5mL tubes. The
University of Kentucky Proteomics Core completed mass spectrometry analysis.

CD274 promoter luciferase assay
NCI-H460, A549, and UKY29 cells were seeded at 2x10 4 cells/well on a 24well plate in 1mL RPMI 1640 containing 10% FBS and incubated at 37°C, 5% CO2
for 24 hours. Media was then replaced with 500µL RPMI 1640 with 1% FBS
containing no antibiotics prior to transfection with SHP-2 siRNA (ThermoFisher)
with RNAiMAX (ThermoFisher) to a concentration of [30nM]. After a 24-hour
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incubation, media was replaced with RPMI 1640 with 10% FBS containing no
antibiotics and cells were transfected with plasmid vectors containing Renilla
luciferase with a TK promoter (Promega #E2241) and firefly luciferase with the
CD274 promoter (Addgene #107003) using Lipofectamine3000 (ThermoFisher).
Additionally, one group of transfected cells were also treated with RMC-4550
(SelleckChem) at [20nM]. Media was removed 24 hours post-transfection, and
cells were washed with 1x phosphate buffered saline. Cells were then lysed by 15
minutes of incubation with 100µL of passive lysis buffer (Promega #E1910) while
rocking at room temperature. To measure luminescence, lysate was warmed to
room temperature and then 20µL was plated onto a white-bottom 96-well plate
(USA Scientific #5665-5074). The Promega dual-luciferase reporter assay system
was then used to measure luminescence with a Synergy H1 multi-mode microplate
reader (BioTek). To control for transfection efficiency, firefly luciferase
luminescence was standardized to Renilla luminescence by dividing the firefly
signal values by the Renilla signal values.

Quantitative real-time PCR (qRT-PCR) analysis

Total RNA was extracted from lysed cells using the RNeasy kit (Qiagen).
cDNA was then generated using the iScript cDNA synthesis kit (BioRad). qRTPCR was performed using human TaqMan primer probe sets (Thermo- Fisher) for
PD-L1 (Assay ID: Hs00204257_m1), SHP-2 (Hs06636344_g1), GAPDH
(Hs02786624_g1) and β-Actin (Hs99999903_m1). qRT-PCR data were analyzed
by calculating ΔCt values for PD-L1 by standardizing PD-L1 Ct values against
those for the averaged Ct values of housekeeping genes GAPDH and β-Actin.

PD-L1 ΔCt = (PD-L1 Ct) – (GAPDH Ct + β-Actin Ct / 2)
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Western blot analysis

Following treatment and harvest, cells were lysed with protein sample
buffer, subjected to at least one -20°C freeze/thaw cycle, sonicated, then heated
to 95°C for 5 minutes prior to protein separation using 10% SDS-polyacrylamide
gel electrophoresis (PAGE) at 135V for 80 minutes. Proteins were transferred to a
nitrocellulose membrane and blocked in Tris-buffered saline (TBS) containing
0.1% Tween 20 and 5% bovine serum albumin for 30 minutes prior to overnight
incubation at 4°C with primary antibody: SHP-2 (#3397), PD-L1 (#13684), or
GAPDH (#2118) (Cell Signaling Technologies). After overnight incubation,
antibody was removed, and blots were washed with TBS containing 0.1% Tween
20. Secondary HRP-labeled antibodies were applied to the blot in 5% non-fat, dry
milk in 1X TBS containing 0.1% Tween 20 for one hour. The blot was washed three
times for 5 minutes each in 1X TBS containing 0.1% Tween prior to developing
and detection of HRP signal. Signal was quantified using ImageJ software (NIH)
and values for SHP-2 and PD-L1 were normalized to GAPDH.

Mass spectrometry

Each gel slice was treated with dithiothreitol (DTT), iodoacetamide (IAA), and
digested with trypsin. The tryptic samples were filtered with 0.22µM PVDF filters
and subject to liquid chromatography-mass spectrometry (LC-MS/MS) analysis.
MS data sets were searched in MASCOT against a custom database containing a
reviewed

dataset

of

Homo

sapiens

proteins

from

Uniprot.

(https://www.uniprot.org/uniprot/?query=taxonomy:%22Homo%20sapiens%20(H
uman)%20%5b9606%5d%22&fil=organism%3A%22Homo+sapiens+%28Human
%29+%5B9606%5D%22+AND+reviewed%3Ayes). The MASCOT files were
filtered with peptide medium confident filter (MCF, target peptide false discovery
rate of 5% for ‘medium’ confidence) to filter out low confidence peptides.
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4.3

Results

SHP-2 ablation changes PD-L1 mRNA and protein half-life

To dissect the mechanism by which SHP-2 influences PD-L1 expression, I
first wanted to determine the role of SHP-2 in either transcription or translation,
using actinomycin D and cycloheximide treatments, respectively. Cycling H460
cells with or without ablation of SHP-2 using siRNA were treated with either
actinomycin D or cycloheximide for 10 hours. siRNA ablation of SHP-2 was chosen
here to reduce toxicity from transfection and allow for sufficient cell numbers for
subsequent treatments. mRNA and protein expression of SHP-2, PD-L1 and
GAPDH were measured by qRT-PCR and western blot, respectively. We
discovered that in cells lacking SHP-2 then subsequently treated with actinomycin
D, both PD-L1 protein and mRNA were degraded more rapidly than in cells
expressing SHP-2 (Figure 4.1A, 4.1B, 4.3). In cells lacking SHP-2 then treated with
cycloheximide, modest changes in PD-L1 protein and mRNA levels were observed
when compared to SHP-2 expressing cells (Figure 4.2A, 4.2B, 4.4). Collectively,
these data suggest that SHP-2 likely functions in regulating mRNA turnover.

SHP-2 ablation increases CD274 promoter activity

To begin investigation of the impact of SHP-2 expression on PD-L1 mRNA
expression, a CD274 promoter-driven luciferase construct was ectopically
expressed to measure whether altering SHP-2 expression influences CD274
promoter activity. I discovered that A549 and UKY29 cells treated with either SHP2 siRNA or RMC-4550 had greater CD274 promoter activity compared to control
(Figure 4.5A, 4.5C). Importantly, these changes in CD274 promoter activity varied
by cell type, with H460 cells demonstrating no differences in CD274 promoter
activity in either treatment.

SHP-2 interacts with proteins involved in mRNA processing and cellular
chaperoning
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Because SHP-2 appears to influence both PD-L1 mRNA and protein halflife, I wanted to determine whether SHP-2 is interacting with other proteins that
might assist in understanding the mechanism used to manage PD-L1 expression.
I sought to identify protein partners of SHP-2 in cells using co-immunoprecipitation
followed by mass spectrometry identification of protein partners. Ectopicallyexpressed SHP-2 was immunoprecipitated from H460 cells and resolved by SDSPAGE. LC-MS/MS was carried out on gel regions subjectively chosen to contain
prominently stained proteins. We then queried the tryptic protein fragments to
determine identification of proteins in that slice. Importantly, the bait protein, SHP2, was among the proteins discovered in our analysis. We then generated a list of
the highest scoring proteins, with scores ranging from 234.93 to 540.88 and amino
acid coverage ranging from 18.33% to 51.98%. Of these proteins, two (HSP7C,
GRP78) have been shown to be involved in the chaperoning and proper folding of
proteins, and the remaining eight (DDX3X, PUF60, CPSF5, EF1A1, EF1A3,
DDX3Y, RSMB, RSMN) have been shown to be involved in transcriptional
regulation/activation and mRNA processing (Table 4.1). These results are
consistent with a role for SHP-2 in either mRNA processing or regulation of
turnover.

SHP-2 expression is not targeted by the proteasome

During this experimentation, I observed that SHP-2 is poorly expressed in
NSCLC cells that are actively growing, consistent with the observations of other
groups (Figure 4.6)(106)(107). Thus, NSCLC cell lines were maintained in low
serum for assays designed to evaluate the impact of SHP-2 activity or expression.
I sought to understand why SHP-2 expression was not expressed in cycling cells
as would be expected of a protein that was crucial for KRAS pathway control. I
suspected that loss of SHP-2 expression was linked to increased proteasomal
degradation in cycling cells.
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To first understand the context of SHP-2 expression as it relates to the cell
cycle, I first cultured cells in low serum media (0.1% FBS), added back serum to a
concentration of 10% FBS, and harvested cells after 1, 2, 4, and 8 hours. I
discovered that in H460 and A549 lines, SHP-2 expression was rapidly and
substantially decreased after 1 hour, and this reduction in expression was
maintained through the 8-hour time point (Figure 4.7). To test if the loss of SHP-2
was mediated by proteasomal degradation, cells were cultured under varying
media conditions for 72 hours followed by treatment with the selective 26S
proteasome inhibitor carfilzomib (CFZ). We found that cells maintained in low
serum conditions (48 hours of 1% FBS RPMI) had the highest levels of SHP-2
expression, compared with cells in high serum conditions. Importantly, SHP-2
expression was unaffected following CFZ treatment, suggesting that the loss of
SHP-2 expression in cycling cells is not due to degradation by the 26S proteasome
(Figure 4.8)

4.4

Discussion
The aim of this final data chapter was to elucidate the mechanism by which

SHP-2 exerts control over PD-L1 expression. In chapter 3, I observed changes in
PD-L1 levels at all layers of expression (mRNA, protein, and surface expression)
in response to genetic ablation of SHP-2 protein. These results suggested that
SHP-2 had multiple roles on PD-L1 expression, but it was important to understand
why. It was discovered that in H460 cells treated with actinomycin D, the half-life
of both PD-L1 mRNA and protein was decreased in cells with reduced SHP-2
expression, while in cells treated with cycloheximide demonstrated minimal
changes in PD-L1 mRNA and protein half-life. Thus, the impact of SHP-2 on PDL1 expression likely resides in the regulation of mRNA half-life rather than by
influencing the translation or turnover of PD-L1 protein, potentially in a manner
similar to that of TTP as described by Coehlo et al. Importantly, these findings
suggest a previously unreported function of SHP-2 in direct control of mRNA
expression and metabolism. With these observations in hand, we further
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hypothesized that SHP-2 serves as a protein scaffold for a multi-protein complex
involved in mRNA turnover. To begin dissecting novel SHP-2 protein-protein
interactions that would support our hypothesis, we performed immunoprecipitation
of

SHP-2

followed

by

mass

spectrometry

analysis

to

identify

co-

immunoprecipitating proteins.

From the bioinformatic perusal of the tryptic peptide sequences from the
mass spectrometry analysis, I uncovered proteins previously identified as: 1)
components of multi protein complexes, 2) participants in mRNA translation and
processing, and 3) chaperones of proteins from the endoplasmic reticulum (ER) to
the cell surface. Of the top 10 scoring proteins from the analysis shown in Table 1,
two have been shown to serve as chaperones for proteins from the endoplasmic
reticulum, and eight are involved in transcriptional regulation, mRNA processing
and maturation. The protein with the most independent hits in the analysis,
HSP7C, plays significant roles in the transport and folding of newly synthesized
polypeptides, the formation and dissociation of protein complexes, and can even
function as a repressor of transcriptional activation (186)(187)(188). The second
highest scoring protein, DDX3X, is a multifunctional RNA helicase involved in a
large variety of cellular processes, specifically with regard to RNA transcription and
metabolism. Importantly, DDX3X contains a tyrosine at residue 104 which may be
phosphorylated and could serve as a potential interaction site for SHP-2 SH2
domains (189). Additionally, DDX3X has been reported to have both tumorpromoting and tumor-suppressive effects, similar to SHP-2, and has been shown
to have deregulated expression in several types of cancer (124)(189)(190).

Having established a connection between SHP-2 expression and PD-L1
mRNA levels in the bioinformatic analyses of tumor data, I wanted to understand
if SHP-2 and its potential protein partners were capable of impacting PD-L1
transcriptional activity by influencing activity of the CD274 promoter. I discovered
that A549 and UKY29 cells with reduced SHP-2 activity or expression maintained
significantly higher levels of CD274 promoter activity than those that express active
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SHP-2 (Figure 4.7). This finding further reinforces our hypothesis that SHP-2
exerts transcriptional control of PD-L1, potentially through its involvement in
upstream signaling pathways such as the RAS/Raf/ERK and Jak/STAT pathways,
both of which have been shown to influence CD274 transcriptional activity
(191)(192). Interestingly, the reductions in SHP-2 activity had minimal impact on
CD274 promoter activity in H460 cells when compared to A549 and UKY29 cells.
Across multiple repetitions, H460 cells demonstrated the lowest levels of CD274
promoter activity of all three cell lines even though they consistently express the
highest levels of PD-L1 protein (as measured by western blot) (Figure 4.6). This
suggests that in some cell types, there are post-transcriptional regulatory events
that modulate the stability of the CD274 mRNA available for translation. It is
important to note that H460 cells with ablated SHP-2 expression demonstrated a
more rapid degradation of PD-L1 mRNA and protein, however SHP-2 knockdown
had no impact on CD274 promoter activity in these cells. Additional repetitions of
the actinomycin D/cycloheximide experiments, also expanded to A549 and UKY29
cells, are necessary to help understand these observations and provide additional
information on if these trends are impacted by cell type. It is also important to
dissect whether there is an impact of SHP-2 at the CD274 promoter that directs
transcription, or if SHP-2 serves a protective role for CD274 mRNA by forming a
complex with eIF1-a and DDX3X at the cap of newly transcribed mRNA that
influences mRNA stability and delivery to the ribosome. Interestingly, treatment
with the SHP-2 allosteric inhibitor RMC-4550 similarly increased CD274 promoter
activity and so the catalytic PTP activity of SHP-2 may bear relevance to
transcriptional control of PD-L1. However, it is still unclear as to what extent the
presence of RMC-4550 impacts the proposed SHP-2 protein complex formation.

From our mass spectrometry screen, we identified 8 proteins that are
involved in mRNA processing, however only one protein (PUF60) has been shown
to directly bind to the promoter region of genes and regulate their transcriptional
activity (193). Additionally, our analysis of RNA-seq data from NSCLC patient
tumors revealed a significant negative correlation (r = -0.253, p<0.0001) between
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PUF60 and CD274 mRNA. Though there remains the possibility of SHP-2’s direct
involvement in a complex that binds to the CD274 promoter, further
experimentation is required to dissect these processes and uncover the
mechanism by which SHP-2 impacts CD274 transcriptional activity.

Finally, the expression of SHP-2 primarily in non-cycling cells made it
difficult to understand how SHP-2 regulates PD-L1 in growing tumor cells. Thus,
in cycling cells, is SHP-2 expressed only for a brief period to transmit a signal or
interact with a protein substrate, followed by prompt SHP-2 degradation or
promoter deactivation? Or are there other mechanisms that limit SHP-2 protein
expression? I hypothesized that SHP-2 may be a target for degradation by the
proteasome in cells that are actively dividing, and that SHP-2 expression in cycling
cells could be both ephemeral and contingent upon the activation of pathways in
which it serves a necessary function. I discovered that cells rapidly lost expression
of SHP-2 after the addition of mitogens to low serum cell media. Within 1 hour
SHP-2 expression was greatly diminished and did not return by the 8-hour time
point. This suggests that regulation of SHP-2 expression is cell-cycle mediated,
and that as cells enter the S-phase of the cell cycle, expression of SHP-2 is lost,
and expression does not return until cells either progress past the S-phase or leave
the cell cycle completely. To determine whether SHP-2 expression is lost due to
proteasomal activity, cells were treated with CFZ after starvation and serum
addition. However, I discovered that CFZ treatment for 8 hours did not prevent the
degradation of SHP-2, suggesting the 26S proteasome is not responsible for this
loss of SHP-2 expression. These observations suggest that SHP-2 expression is
differentially modulated by the replicative status of malignant cells, which is an
important consideration for pharmacologically inhibiting SHP-2 in vivo.

Each of the findings in this chapter are also important to consider within the
context of a human tumor in situ. As noted in earlier chapters, NSCLC tumors are
comprised of not one singular cell type, but of heterogenous sub-populations of
cells. As a tumor grows it will recruit blood vessels through the process of
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angiogenesis to acquire sufficient amounts of oxygen and mitogenic factors.
However, tumor angiogenesis is not an efficient or articulate process, and so it
may render parts of the tumor devoid of sustenance, specifically areas like the core
of tumor, which may become populated by necrotic tissue (194)(195)(196). My
findings suggest that SHP-2 expression, and its influence on PD-L1 expression,
may be most prevalent in specific areas of a tumor, such as the core, with slowed
growth. Furthermore, it suggests that SHP-2 is of greater importance to cells under
conditions in which survival is of greater importance than replication. Further
experimentation, such as immunohistochemical interrogation of KRAS-active
NSCLC tumor biopsies for the co-occurrence of SHP-2 and PD-L1, is required to
understand whether the in vitro expression patterns mirror that of an actual tumor.

4.5

Conclusions
The experimentation in this chapter imparts evidence that SHP-2 regulates

PD-L1 mRNA half-life. Further, CD274 promoter activity was impacted by a loss of
SHP-2 expression, thereby further narrowing the scope of SHP-2 to a
transcriptional regulatory role. Although SHP-2 is not expressed as cells enter Sphase, evidence presented here shows that SHP-2 is not degraded by the 26S
proteasome in actively cycling NSCLC cells. Additional experimentation should
include studies to determine the mechanisms controlling SHP-2 expression in
cycling cells. Finally, using the information gleaned from the immunoprecipitation
analyses, I predict that multi-protein complexes, controlled by transient SHP-2
expression, are the regulatory agents of PD-L1 control. These observations hold
both clinical and basic biological implications. Ablation of SHP-2 may synergize
with PD-L1 blockade in NSCLC and may be predicted by the expression levels of
PD-L1 from a biopsy as standard of care. Thus, dissection of the unreported
activities of SHP-2 protein complexes in the regulation of mRNA processing and
trafficking of PD-L1 may offer additional insights for both biomarkers and therapy.
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Figure 4.1. SHP-2 expression influences PD-L1 protein half-life in
actinomycin D treated cells. A. NCI-H460 cells were seeded at 2x104
cells/well on a 24-well plate in RPMI 1640 containing 10% FBS and
incubated at 37°C, 5% CO2 for 24 hours. Media was then removed and
replaced with RPMI 1640 containing 10% FBS and no antibiotics prior to
transfection with SHP-2 siRNA [30nM] for 48 hours prior to treatment with
actinomycin D [1ug/mL] and timepoints were taken every 2 hours for 10
hours. B. Densitometric quantification of the representative western blot of
PD-L1 signal normalized to GAPDH in actinomycin D treated cells.

A

B
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Figure 4.2. SHP-2 expression modestly influences PD-L1 protein
half-life in cycloheximide treated cells. A. NCI-H460 cells were
seeded at 2x104 cells/well on a 24-well plate in RPMI 1640 containing
10% FBS and incubated at 37°C, 5% CO2 for 24 hours. Media was
then removed and replaced with RPMI 1640 containing 10% FBS and
no antibiotics prior to transfection with SHP-2 siRNA [30nM] for 48
hours prior to treatment with cycloheximide [10ug/mL] and timepoints
were taken every 2 hours for 10 hours. B. Densitometric quantification
of the representative western blot of PD-L1 signal normalized to
GAPDH in cycloheximide treated cells.

A

B
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Figure 4.3. SHP-2 expression influences PD-L1 mRNA half-life in
actinomycin D treated cells. A Time-course of mRNA expression levels
of CD274 (PD-L1) in NCI-H460 cells treated as previously described in
Figure 4.1 with actinomycin D.
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Figure 4.4. SHP-2 expression does not impact PD-L1 mRNA half-life
in cycloheximide treated cells. A Time-course of mRNA expression
levels of CD274 (PD-L1) in NCI-H460 cells treated as previously described
in Figure 4.2 with cycloheximide.
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Figure 4.5. CD274 transcriptional activity is increased in cells with
ablated SHP-2 activity or expression. A. Ectopic expression of a
CD274 promoter driven luciferase cassette (pGL3 2 kb prom. CD274) in
A549 cells, B. H460 cells, or C. UKY29 cells either untreated after
transfection or treated with SHP-2 siRNA [30nM] or RMC-4550 [20nM].
Firefly luminescence expression was normalized to Renilla luminescence
signal driven by the thymidine kinase promoter.

A
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Figure 4.6. SHP-2 is not expressed in actively cycling cells. NCI-H460,
A549, and UKY29 cells were seeded at 2x104 cells/well in a 24-well plate in
1mL of RPMI 1640 containing 10% FBS and incubated at 37°C, 5% CO 2
for 24 hours. Cells labeled 1% and S+ then had media removed and
replaced with RPMI 1640 containing 1% FBS. After 24 hours, cells labeled
S+ had FBS added back to a final concentration of 10% and were allowed
to incubate for another 24 hours prior to harvest. Cells labeled 10%
remained in 10% media for the full 72 hours.
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Figure 4.7. SHP-2 expression is lost as cells re-enter the cell cycle. NCIH460 and A549 cells were seeded at 2x105 cells/well in all well of a 6-well
plate in 3mL of RPMI 1640 containing 10% FBS and incubated at 37°C, 5%
CO2 for 24 hours. For five of the wells, media was then replaced with 3mL
RPMI 1640 containing 0.1% FBS. After 24 hours, FBS was added back to
four of the starved wells and cells were harvested 1, 2, 4, and 8 hours post
addition of FBS. Lanes labeled 10% remained in 10% media for 48 hours,
and well labeled 1% were harvested 24 hours after being changed to 1%
media.
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Figure 4.8. Carfilzomib treatment has no impact on SHP-2
degradation. For carfilzomib treatments, NCI-H460, A549, and UKY29
cells were seeded at 2x104 cells/well on a 24-well plate in 1mL RPMI 1640
containing 10% FBS and incubated at 37°C, 5% CO2 for 24 hours. Cells
then were allowed to either remain in 10% FBS RPMI 1640 for an
additional 48 hours, or media was replaced with 1mL of 1% FBS RPMI
1640 and allowed to incubate another 24 hours (lanes labeled 1%). Finally,
designated cells had media removed and replaced with 10% FBS RPMI
1640 for 24 hours. Carfilzomib and/or FBS to a final concentration of 10%
FBS were added 72 hours after initial seeding to designated wells to a final
concentration of [50nM] for 8 hours prior to harvest. Wells labeled S+
received FBS for 8 hours in addition to carfilzomib.
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Table 4.1. Top 10 scoring proteins identified in LS-MS/MS analysis.
Mass spectrometry analysis of proteins which co-immunoprecipitated
with SHP-2, ranked by percent coverage and categorized by function.

Protein

Score

SHP-2
HSP7C

648.58
540.88

%
Coverage
48.57
35.29

DDX3X

511.12

33.08

PUF60

482.65

30.77

CPSF5

387.32

51.98

EF1A1

353.86

35.06

EF1A3

353.86

35.06

DDX3Y

353.09

24.55

GRP78

321.38

22.94

RSMB

244.19

18.33

RSMN

244.19

18.33

Function
Protein tyrosine phosphatase
Chaperone, protein folding, proteolysis
activation
RNA-helicase, binds rG4s structures
DNA/RNA binding protein, RNA splicing,
transcription regulation
Cleavage factor complex, activator of
pre-mRNA-3' cleavage
Promotes tRNA binding during peptide
synthesis
Promotes tRNA binding during peptide
synthesis
RNA-helicase, binds rG4s structures
ER chaperone, protein folding, degrades
misfolded proteins
pre-mRNA splicing, SMN-Sm complex,
component of snRNPs
pre-mRNA splicing, SMN-Sm complex,
component of snRNPs
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CHAPTER 5.

5.1

Overview
The work described herein utilizes the immense power of publicly available

gene and protein expression data to serve as a quick and effective tool to form a
foundation upon which the logical development of a discretely testable hypothesis
may be formatted for benchtop laboratory experimentation. Given the importance
of SHP-2 to numerous oncogenic pathways, the multifaceted functionality of SHP2 as both a tyrosine phosphatase and a protein scaffold, and the strong correlation
between SHP-2 activity and PD-L1 protein expression in patient tumors, I
hypothesized that SHP-2 regulates PD-L1 expression through the
enucleation of a protein complex that influences PD-L1 mRNA expression
and metabolism.

Indeed, the findings described in this work bear clinical and translational
significance by suggesting that inhibition or targeted degradation of SHP-2 may
synergize with PD-L1 blockade, especially in KRAS-driven NSCLC. An important
caveat of this suggestion is the lack of SHP-2 in growing cells, or at least those in
S-phase. However, the true value of this work lies not in the expedited application
of synergistic drug combinations, but rather in the expansion of knowledge
regarding the basic biology behind the anomalous utilization of immune checkpoint
proteins by malignant cells. Though arguably the greatest achievement in cancer
therapy of this century, the optimal application of immune checkpoint inhibitors
remains restricted by a lack of understanding behind the regulatory mechanisms
that govern ICI target expression. These studies, through the interrogation of the
molecular mechanisms underpinning PD-L1 expression, function to ameliorate the
shortcomings of modern ICI therapeutic interventions. Furthermore, the
investigation of the biological relationship between SHP-2 and PD-L1 has revealed
the potential of previously unreported functions of SHP-2 in the trafficking of

proteins and processing of mRNA. These revelations present the potential for new
therapeutic avenues that manipulate these novel mechanisms of PTPs in cancer,
further accentuating the value of basic biology research in the field of cancer
therapeutics.

Summary of Results

To begin my exploration into the relationship between SHP-2 and PD-L1
expression, I turned first to one of the most powerful cancer informatic databases
available to date: The Cancer Proteome Atlas, and the NCI Genetic Data
Commons. These databases contain protein and gene expression data with
substantial sample sizes of real-world patient tumors across a plethora of cancer
subtypes. Additionally, I looked to the Gene Expression Omnibus (GEO), a
database that serves as depository for published results. While the data contained
in the TCPA/GDC predates the advent of ICIs in the clinic, GEO provides data from
smaller studies that, in some cases, collected gene expression data from patients
who did or did not respond to ICI therapy. Together, the information contained in
these three databases was used to address two research questions: does there
exist a correlation between SHP-2 activity/expression and PD-L1 expression,
and does the expression of SHP-2 correlate to response to ICI therapy?

Upon interrogation of reverse-phase protein array data for lung
adenocarcinoma (LUAD) patients (n=362) I uncovered a significant negative
correlation between active SHP-2 and PD-L1 protein levels. Interestingly, when I
analyzed mRNA expression of SHP-2 and PD-L1 for these same 362 patient
tumors, I uncovered no significant correlations in mRNA levels. Upon expanding
our analysis to the entire LUAD dataset (n=585), I discovered a slight and
significant positive correlation in SHP-2 and PD-L1 mRNA. These findings suggest
that these two proteins may be co-expressed in NSCLC tumors, and the activity of
SHP-2 is used to more finely tune tumoral expression of PD-L1.

103

Next, I turned to GEO to find smaller studies that analyzed malignant cells
for SHP-2 and PD-L1 expression that also contained data for response to immune
checkpoint inhibition, as the GDC/TCPA was lacking ICI response data. I found
that, although PTPN11 mRNA expression maintained no significant correlation to
ICI response in both melanoma or NSCLC, PTPN11 and CD274 mRNA did weakly
associate in melanoma. Furthermore, I found that CD274 mRNA levels were
associated with response to ICI in NSCLC tumors, an observation made by many
others that supports the current clinical ICI treatment recommendation of ICI usage
in patients with tumors with a PD-L1 tumor proportion score ≥50%.

Finally, I conducted a similar correlation analysis of proteins that coprecipitate with SHP-2 in KRAS-active NSCLC cells, detailed in chapter 4. The
protein which I had the most interest in, DDX3X, had a strong positive correlation
with SHP-2, suggesting that these proteins are indeed co-expressed not only in
NSCLC cells in vitro, but in real-world patient tumors as well. Additionally, both
DDX3X protein and mRNA are expressed in cycling and non-cycling H460, A549
and UKY29 cells

Following the insight gained from our bioinformatic analysis, I used several
methods to ablate SHP-2 expression and activity and measured their effects on
PD-L1 expression at the levels of mRNA, total protein, and cell surface protein. I
hypothesized that reductions in SHP-2 activity or expression would result in
increases to PD-L1 expression in KRAS-active NSCLC cells. I used two
allosteric inhibitors (SHP099 and RMC-4550) to inhibit the phosphatase activity of
SHP-2. To diminish SHP-2 expression, I used both siRNA to prevent PTPN11
mRNA translation, and CRISPR/Cas9 mediated knockout to edit the PTPN11
genomic template and prevent PTPN11 mRNA expression altogether.

My experimentation revealed that changes in PD-L1 expression were
primarily in response to genetic ablation of SHP-2 protein, rather than
pharmacological inhibition. Genetic ablation of SHP-2 removes both its ability to
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enucleate protein complexes and its catalytic phosphatase activity. Allosteric
inhibition of SHP-2 prevents phosphatase activity, but it is unknown to what extent
this type of inhibition influences protein-protein interactions of SHP-2. However, it
is important to note that the TCPA dataset did not contain expression data for total
SHP-2, only for pY542-SHP-2. At the mRNA and total protein levels we observed
a significant increase in PD-L1 expression following SHP-2 CRISPR knockouts,
but not with siRNA knockdowns. At the level of cell surface expression, I again
observed significant increases in PD-L1 levels in cells with diminished SHP-2
expression. Taken together, our findings provide a novel mechanism for the
aberrant expression of PD-L1 in KRAS-active NSCLC.

Having observed increases in PD-L1 at multiple levels of expression
following SHP-2 knockout, but not small molecule inhibition, I next hypothesized
that multiprotein complexes enucleated by SHP-2 are the regulatory agents
of transcriptional control of PD-L1. To test this, I began by using actinomycin D
and cycloheximide to measure the impact of SHP-2 knockdown on PD-L1 mRNA
and protein half-life. I discovered that cells lacking SHP-2 and treated with
actinomycin D, both PD-L1 protein and mRNA were more rapidly degraded (and
to a lesser extent the same was observed with cycloheximide) suggesting that
SHP-2 likely functions in regulating mRNA turnover. I immunoprecipitated SHP-2
coupled with mass spectrometry to identify co-precipitating protein partners.
Interestingly, the top ten scoring proteins were involved in either mRNA processing
or as ER chaperones, observations concurrent with my discoveries from chapter
3. These findings are highly significant as they suggest previously unreported
functions of SHP-2 complexes in the regulation of mRNA turnover and protein
trafficking but will require more experimentation to definitively understand.

I followed up on these observations by utilizing a luciferase reporter assay
to measure the transcriptional activity of the CD274 promoter in the presence or
absence of SHP-2. I discovered that SHP-2 knockdown cells had higher levels of
CD274 promoter activity than those expressing SHP-2, though importantly, this
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varied by cell type. It is worth noting that H460 cells, the cell line I used to measure
mRNA stability, had no changes in promoter activity following SHP-2 ablation or
inhibition. This suggests that the function of the proposed SHP-2 complex may not
be to directly interact with the CD274 promoter, but rather to post-transcriptionally
regulate mRNA. Though all three cell lines harbor activating mutations in the KRAS
gene, they also harbor additional mutations in pathways known to regulate PD-L1
transcriptional activity. For example, H460 cells harbor an activating mutation in
PIK3CA, the catalytic subunit of the PI3K complex. Constitutive activation of this
pathway may be responsible for the high levels of CD274 transcriptional activity in
untreated H460 cells and may serve as an explanation for why diminished SHP-2
activity/expression had no impact on CD274 promoter activity in these cells (74).

Finally, I used the selective proteasome inhibitor carfilzomib and stratified
media conditions to discern under what conditions cells express SHP-2 and
investigate a potential mechanism of SHP-2 turnover. I found that as cells enter Sphase, SHP-2 expression is rapidly diminished, though not through proteasomal
degradation. It is possible that ablation of SHP-2 activity in these cell lines impacts
CD274 mRNA expression at multiple levels; first, by disrupting the transmission of
signaling cascades that positively regulate CD274 mRNA expression (such as the
RAS/Raf/ERK cascade) (83)(106)(107), and then also by preventing the formation
of SHP-2 protein complexes which negatively regulate CD274 mRNA stability or
metabolism, as suggested by my own experimentation.

Indeed, the complex interplay between these proteins and the manner by
which they interact and intersect at multiple nodes of molecular operations poses
a great challenge in elucidating the mechanism of SHP-2s regulation of PD-L1.
Future experimentation which picks apart the involvement of SHP-2 in these
signaling cascades from my newly proposed mechanisms of SHP-2 complexes in
mRNA processing will be necessary to elucidate the role of SHP-2 in the
expression of PD-L1.
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Experimental limitations

In these studies, I combined the power of publicly available gene and
protein expression data with benchtop biochemical analysis to test my hypothesis
that SHP-2 influences PD-L1 expression in KRAS-active NSCLC. Through this
analysis, I demonstrated that SHP-2 activity and expression impact PD-L1 levels
both in patient NSCLC tumors and in vitro cell culture. Furthermore, I began
investigating possible mechanisms by which SHP-2 does this and uncovered
previously unreported functions of SHP-2 as well as provide a mechanism for SHP2 degradation in replicating cells. Though I am confident in both the reliability and
reproducibility of these findings, there are important considerations that must not
be ignored regarding the experimental design and biological/bioinformatic models
applied in these studies.

Through my analysis of protein expression data deposited on TCPA, I
uncovered a significant negative correlation between SHP-2 activity and PD-L1
expression. However, the TCPA data did not include expression levels of total
SHP-2 protein, only the Y542 activated form. As a result of this, I am unable to
dissect the impact of inactive from active SHP-2, particularly as it relates to the
catalytic phosphatase activity of the protein verses its protein enucleation
capabilities. The TCPA data also did not include protein expression for any of the
top 10 identified protein hits from the mass spec screen, limiting the usefulness of
the combined bioinformatic/biochemical methods used. Though the sample size of
TCPA NSCLC patient samples was still several hundred (n=362) this was still a
subset of the full TCGA-LUAD data set (n=585) and thus further limited the power
of the analysis. Thankfully, these shortcomings were attenuated by the more
complete data contained in the GDC, however this dataset too had its own
limitations. One aim of my bioinformatic analyses was to understand how SHP-2
expression correlated to ICI response, but the GDC contained incomplete or
missing drug response data. And lastly, the datasets acquired from GEO were
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limited by either small sample sizes (n<30), non-NSCLC patient samples, or not
entirely complete ICI response data.

Following the results of my informatic analyses, I tested the effects of
diminished SHP-2 activity or expression on PD-L1 expression in KRAS-active
NSCLC cells. The major limitation of these studies is that all my work was confined
to cell-based assays, and so the scope of my observations does not cross into how
the expression of these two proteins relate within an actual living organism. I also
observed that expression of SHP-2 was greatly reduced in cells that are actively
cycling, and so to allow for the expression of the target of my small molecules and
genetic knockouts, it was necessary to culture the cells in low serum containing
media. The fact that cells were not cycling in these experiments results in
alterations in the expression of genes that regulate cell cycle progression, or those
that are expressed more strongly in conditions in which survival outweighs
proliferation. Though these cells were certainly impacted on a molecular level by
the lack of mitogenic factors which disallowed cell cycle progression, this model
does indeed reflect the hypoxic, mitogen devoid conditions and non-cycling cell
populations that exist within actual tumors. In my experiments that called for
ablated SHP-2 expression, the differential efficacy of siRNA versus CRISPR/Cas9
mediated knockdown is not to be ignored. Furthermore, the transfection of these
cells with lipid complexes had increased toxicity compared to that of the small
molecule inhibitors, and so the less efficacious (and also less toxic) method of
siRNA ablation was more appropriate for experiments involving cycloheximide or
actinomycin D. Additionally, both the cycloheximide/actinomycin D and coimmunoprecipitation experiments were carried out only in the H460 cell line, not in
A549 or UKY29 cells. Lastly, though the clinicogenomic analyses of my top ten
mass spec hits provided additional evidence for the co-expression and potential
interactions of these proteins and SHP-2, reverse pulldowns of the identified
proteins followed by analysis for the presence of SHP-2 is required to reinforce my
conclusions.
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Conclusions and future directions

The work described herein successfully identified SHP-2 as a protein that
could influence the expression of PD-L1 through the combined application of
cancer informatics and biochemical analyses. In doing so, I also uncovered new
information about the biological functions of SHP-2 in NSCLC cells. In these
studies, I demonstrated the usefulness and power of informatic analyses of publicly
available datasets such as TCPA and GDC, which helped to focus the aim of my
biochemical experimentation and expedite the interrogation of my hypotheses. My
most significant finding is a new mode of regulation for PD-L1 in NSCLC cells
through the activity and expression of SHP-2. Furthermore, these observations
suggest that the inhibition of SHP-2 would synergize with PD-L1 blockade in
NSCLC patients, which bears a great deal of clinical relevance as SHP-2 inhibitors
are already on their way through clinical trials. Through my biochemical analyses,
I also was able to uncover several previously unreported biological functions of
SHP-2. First, of the top ten hits from my mass spec analysis, eight of these proteins
are directly involved in the regulation and processing of mRNA, which until now,
SHP-2 was not known to interact with. The other two proteins identified were both
ER chaperone proteins, again suggest another previously unknown function in the
trafficking of proteins to the cell surface.

Based upon my findings, my working hypothesis is that SHP-2 forms a
complex with the RNA helicase DDX3X and eIF-1a at the cap of newly transcribed
mRNA that functions to negatively regulate PD-L1 expression (Figure 5.1). It may
do this by altering mRNA stability or half-life, or by participating in the chaperoning
of CD274 mRNA to the ribosome, impacting the translation of CD274 mRNA into
protein. At the same time, there also exists the possibility that ablation of SHP-2,
specifically in KRAS active cells, diminishes the activity of signaling pathways
known to positively influence PD-L1 transcriptional activity, thus simultaneously
increasing PD-L1 expression through the removal of the negative regulatory SHP109

2 complex and decreasing PD-L1 expression through the reduced activation of
intersecting signaling pathways.

Moving forward, I plan to continue my investigation of GEO datasets which
include NSCLC patient tumors treated with ICIs as more mature data for ICI
treatment in this tumor subtype becomes available. I have also generated both
hyperactive and catalytically inactive mutants of SHP-2 which I plan to transfect
into these same cells and observe their impact on PD-L1 expression and which
may help to dissect the roles of SHP-2 signal transduction from complex formation
as they relate to CD274 mRNA expression. The findings of the mass spec
screening provide many potential avenues for further experimentation, however I
have chosen the most promising candidate, DDX3X, to be the first protein for which
I conduct reverse immunoprecipitation to confirm its interaction with SHP-2.
Furthermore, I will knock out DDX3X with CRISPR/Cas9 and conduct a similar
analysis to that detailed in chapter 3. Lastly, my finding that SHP-2 is not degraded
by the proteasome in actively cycling cells, but through a different unknown
mechanism, lays the groundwork for additional experimentation that further details
the precise nature of how and why replicating NSCLC cells eliminate SHP-2.
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Figure 5.1. Working hypothesis for the mechanism of PD-L1
regulation by SHP2-. SHP-2 forms a complex with the RNA helicase
DDX3X and eIF-1a at the cap of newly transcribed mRNA that functions
to negatively regulate PD-L1 expression. It may do this by altering
mRNA stability or half-life, or by participating in the chaperoning of
CD274 mRNA to the ribosome, impacting the translation of CD274
mRNA into protein.

3’
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CD274 mRNA

CD274

APPENDIX 1. TABLE OF ABBREVIATIONS

Abbreviation
VEGF
HIF-a
p53
Bax
Bcl-2
ABL1
BCR
EGFR/Her-2
PI3K
Akt
mTOR
JAK
STAT
SHP-2
PTEN
CD4
CD8
PD-1
PD-L1
KRAS
BRAF
ALK
MET
ROS
STK11
SOS
Grb2
Raf
MEK
Erk
TIAM1
Rac
Rho
PLC
PKC
CTLA-4

Gene name
VEGF
HIF-a
TP53
BAX
BCL2
ABL1
BCR
EGFR
PIK3CA
PKB
MTOR
JAK
STAT
PTPN11
PTEN
CD4
CD8
PDCD1
CD274
KRAS
BRAF1
ALK
MET
ROS1
STK11
SOS1
GRB2
RAF1
MAP2K
MAPK1
TIAM1
RAC1
RHO
PLCG1
PRKCA
CD152

Protein name
Vascular endothelial growth factor
Hypoxia-inducible factor 1-alpha
Cellular tumor antigen p53
Apoptosis regulator BAX
B-cell lymphoma 2
ABL proto-oncogene 1
Breakpoint cluster region protein
Epidermal growth factor receptor
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase
Protein kinase B
Mammalian target of rapamycin
Janus Kinase
Signal transucer and activator of transcription
SH2 containing protein tyrosine phosphatase
Phosphatase and tensin homolog
Cluster of differentiation 4
Cluster of differentiation 8
Programmed cell death protein receptor 1
Programmed cell death protein ligand 1
Kirsten ras oncogene homolog
B-Raf Proto-Oncogene, Serine/Threonine Kinase
ALK Receptor Tyrosine Kinase
MET proto-oncogene receptor tyrosine kinase
ROS Proto-oncogene 1
Serine/threonine kinase 11
Son of Sevenless nucleotide exhange factor
growth factor receptor bound protein 2
Raf-1 proto-oncogene serine/threonine kinase
Mitogen-activated protein kinase kinase 1
Mitogen-activated protein kinase 1
TIAM Rac1 Associated GEF1
Rac family small GTPase 1
Rhodopsin
Phospholipase C Gamma 1
Protein kinase C
Cytotoxic T-lymphocyte-associated protein 4
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CD28
TCR
B7
PTPRG
PRL

CD28
TRA
CD80
PTPRG
PRL

Cluster of differentiation 29
T-cell receptor alpha
B-lymphocyte activation antigen B7
Receptor-type tyrosine protein phosphatase gamma
Prolactin
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